Acronyms of Clinical Trial Names: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +) |
||
(23 intermediate revisions by 4 users not shown) | |||
Line 2: | Line 2: | ||
{{CMG}} | {{CMG}} | ||
''For other acronyms involved in clinical trials, click [[Clinical trial acronyms|here]]'' | ''For other acronyms involved in clinical trials, click [[Clinical trial acronyms|here]]'' | ||
Line 11: | Line 11: | ||
{| cellspacing="1" cellpadding="1" border="1" | {| id="acronyms" cellspacing="1" cellpadding="1" border="1" | ||
| '''''Acronym''''' | | '''''Acronym''''' | ||
| '''''Trial Name''''' | | '''''Trial Name''''' | ||
Line 21: | Line 21: | ||
| [[Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel]] | | [[Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel]] | ||
|- | |- | ||
| 4D | | [[4D]] | ||
| [[Deutsche Diabetes Dialysis Study]] | | [[Deutsche Diabetes Dialysis Study]] | ||
|- | |- | ||
| 4E | | [[4E]] | ||
| [[Efficacy And Safety Of Eplerenone, Enalapril, And Eplerenone/Enalapril Combination Therapy In Patients With Left Ventricular Hypertrophy]] | | [[Efficacy And Safety Of Eplerenone, Enalapril, And Eplerenone/Enalapril Combination Therapy In Patients With Left Ventricular Hypertrophy]] | ||
|- | |- | ||
| 4S | | [[4S]] | ||
| [[Scandinavian Simvastatin Survival Study]] | | [[Scandinavian Simvastatin Survival Study]] | ||
|- | |- | ||
| 6C trial | | [[6C trial]] | ||
| [[Cooperative Colorectal Cancer Combination Chemotherapy Clinical]] | | [[Cooperative Colorectal Cancer Combination Chemotherapy Clinical]] | ||
|- | |- | ||
| A to Z, Phase A | | [[A to Z, Phase A]] | ||
| [[Aggrastat To Zocor]] | | [[Aggrastat To Zocor]] | ||
|- | |- | ||
| A to Z, Phase Z | | [[A to Z, Phase Z]] | ||
| [[Evaluation Of Early Versus Delayed Initiation Of Simvastatin In Patients Who Receive Guideline Based Treatment For Acute Coronary Syndrome]] | | [[Evaluation Of Early Versus Delayed Initiation Of Simvastatin In Patients Who Receive Guideline Based Treatment For Acute Coronary Syndrome]] | ||
|- | |- | ||
| A4 Study | | [[A4 Study]] | ||
| [[Catheter Ablation Versus Antiarrhythmic Drugs For Atrial Fibrillation]] | | [[Catheter Ablation Versus Antiarrhythmic Drugs For Atrial Fibrillation]] | ||
|- | |- | ||
| AAASPS | | [[AAASPS]] | ||
| [[African American Antiplatelet Stroke Prevention Study]] | | [[African American Antiplatelet Stroke Prevention Study]] | ||
|- | |- | ||
| AACHEN | | [[AACHEN]] | ||
| [[Angiotensin II Receptor Blocker Candesartan Cilexetil On Intimal Hyperplasia After Coronary Stent Implantation]] | | [[Angiotensin II Receptor Blocker Candesartan Cilexetil On Intimal Hyperplasia After Coronary Stent Implantation]] | ||
|- | |- | ||
| AASK | | [[AASK]] | ||
| [[African American Study Of Kidney Disease And Hypertension]] | | [[African American Study Of Kidney Disease And Hypertension]] | ||
|- | |- | ||
| ABACAS | | [[ABACAS]] | ||
| [[Adjunctive Balloon Angioplasty Following Coronary Atherectomy Study]] | | [[Adjunctive Balloon Angioplasty Following Coronary Atherectomy Study]] | ||
|- | |- | ||
| ABC study | | [[ABC study]] | ||
| [[Association Of Black Cardiologists Study Of Hypertension]] | | [[Association Of Black Cardiologists Study Of Hypertension]] | ||
|- | |- | ||
| ABCD | | [[ABCD]] | ||
| [[Alternans Before Cardioverter Defibrillator]] | | [[Alternans Before Cardioverter Defibrillator]] | ||
|- | |- | ||
| AbESTT | | [[AbESTT]] | ||
| [[Abciximab Emergent Stroke Treatment Trial]] | | [[Abciximab Emergent Stroke Treatment Trial]] | ||
|- | |- | ||
| ABOARD | | [[ABOARD]] | ||
| [[Immediate Versus Next Day Catheterization In Non-St Elevation Acute Coronary Syndrome]] | | [[Immediate Versus Next Day Catheterization In Non-St Elevation Acute Coronary Syndrome]] | ||
|- | |- | ||
| ABSORB: 6-month and 2-year results | | [[ABSORB: 6-month and 2-year results]] | ||
| [[A Bioabsorbable Everolimus-Eluting Coronary Stent System For Patients With Single De-Novo Coronary Artery Lesions]] | | [[A Bioabsorbable Everolimus-Eluting Coronary Stent System For Patients With Single De-Novo Coronary Artery Lesions]] | ||
|- | |- | ||
| ACADEMIC | | [[ACADEMIC]] | ||
| [[Azithromycin In Coronary Artery Disease: Elimination Of Myocardial Infection With Chlamydia]] | | [[Azithromycin In Coronary Artery Disease: Elimination Of Myocardial Infection With Chlamydia]] | ||
|- | |- | ||
| ACAS | | [[ACAS]] | ||
| [[Asymptomatic Carotid Atherosclerosis Study]] | | [[Asymptomatic Carotid Atherosclerosis Study]] | ||
|- | |- | ||
| ACC AMI GAP | | [[ACC AMI GAP]] | ||
| [[American College Of Cardiology Acute Myocardial Infarction Guidelines Applied To Practice Study]] | | [[American College Of Cardiology Acute Myocardial Infarction Guidelines Applied To Practice Study]] | ||
|- | |- | ||
| ACCENT | | [[ACCENT]] | ||
| [[A Crohn's Disease Clinical Trial Evaluating Infliximab In A New Long-Term Treatment Regimen]] | | [[A Crohn's Disease Clinical Trial Evaluating Infliximab In A New Long-Term Treatment Regimen]] | ||
|- | |- | ||
| ACCEPT | | [[ACCEPT]] | ||
| [[The Accupril Canadian Clinical Evaluation And Patient Teaching Study]] | | [[The Accupril Canadian Clinical Evaluation And Patient Teaching Study]] | ||
|- | |- | ||
| ACCESS | | [[ACCESS]] | ||
| [[Acute Candesartan Cilexetil Evaluation In Stroke Survivors]] | | [[Acute Candesartan Cilexetil Evaluation In Stroke Survivors]] | ||
|- | |- | ||
| ACCLAIM | | [[ACCLAIM]] | ||
| [[Advanced Chronic Heart Failure Clinical Assessment Of Immune Modulation Therapy]] | | [[Advanced Chronic Heart Failure Clinical Assessment Of Immune Modulation Therapy]] | ||
|- | |- | ||
| ACCOMPLISH | | [[ACCOMPLISH]] | ||
| [[Avoiding Cardiovascular Events Through Combination Therapy In Patients Living With Systolic Hypertension]] | | [[Avoiding Cardiovascular Events Through Combination Therapy In Patients Living With Systolic Hypertension]] | ||
|- | |- | ||
| ACCORD | | [[ACCORD]] | ||
| [[Action To Control Cardiovascular Risk In Diabetes]] | | [[Action To Control Cardiovascular Risk In Diabetes]] | ||
|- | |- | ||
| ACCT | | [[ACCT]] | ||
| [[Sex And Age Related Antihypertensive Effects Of Amlodipine]] | | [[Sex And Age Related Antihypertensive Effects Of Amlodipine]] | ||
|- | |- | ||
| ACCURACY | | [[ACCURACY]] | ||
| [[Assessment By Coronary Computed Tomographic Angiography Of Individuals Undergoing Invasive Coronary Angiography]] | | [[Assessment By Coronary Computed Tomographic Angiography Of Individuals Undergoing Invasive Coronary Angiography]] | ||
|- | |- | ||
| ACE | | [[ACE]] | ||
| [[Abciximab-Carbostent Evaluation]] | | [[Abciximab-Carbostent Evaluation]] | ||
|- | |- | ||
| ACE | | [[ACE]] | ||
| [[Anticoagulation For Cardioversion Using Enoxaparin]] | | [[Anticoagulation For Cardioversion Using Enoxaparin]] | ||
|- | |- | ||
| ACE (Carotid Endarterectomy) | | [[ACE (Carotid Endarterectomy)]] | ||
| [[Asa And Carotid Endarterectomy Trial]] | | [[Asa And Carotid Endarterectomy Trial]] | ||
|- | |- | ||
| ACES | | [[ACES]] | ||
| [[Azithromycin And Coronary Events Study In Patients With Stable Coronary Disease]] | | [[Azithromycin And Coronary Events Study In Patients With Stable Coronary Disease]] | ||
|- | |- | ||
| ACES | | [[ACES]] | ||
| [[Clinical Experience Study]] | | [[Clinical Experience Study]] | ||
|- | |- | ||
| ACIP | | [[ACIP]] | ||
| [[Asymptomatic Cardiac Ischemia Pilot Study]] | | [[Asymptomatic Cardiac Ischemia Pilot Study]] | ||
|- | |- | ||
| ACME | | [[ACME]] | ||
| [[Angioplasty Compared To Medicine]] | | [[Angioplasty Compared To Medicine]] | ||
|- | |- | ||
| ACME-2 | | [[ACME-2]] | ||
| [[Angioplasty Compared To Medicine - Two-Vessel Disease]] | | [[Angioplasty Compared To Medicine - Two-Vessel Disease]] | ||
|- | |- | ||
| A-COMET-I | | [[A-COMET-I]] | ||
| [[Azimilide—Cardioversion Maintenance Trial–I]] | | [[Azimilide—Cardioversion Maintenance Trial–I]] | ||
|- | |- | ||
| A-COMET-II | | [[A-COMET-II]] | ||
| [[Azimilide—Cardioversion Maintenance Trial–II]] | | [[Azimilide—Cardioversion Maintenance Trial–II]] | ||
|- | |- | ||
| ACORN | | [[ACORN]] | ||
| [[Assessment Of A Cardiac Support Device (Csd) In Patients With Heart Failure]] | | [[Assessment Of A Cardiac Support Device (Csd) In Patients With Heart Failure]] | ||
|- | |- | ||
| ACRE | | [[ACRE]] | ||
| [[Appropriateness Of Coronary Revascularization]] | | [[Appropriateness Of Coronary Revascularization]] | ||
|- | |- | ||
| ACST | | [[ACST]] | ||
| [[Asymptomatic Carotid Surgery Trial]] | | [[Asymptomatic Carotid Surgery Trial]] | ||
|- | |- | ||
| ACT | | [[ACT]] | ||
| [[Effects Of Physical Activity Counseling In Primary Care: The Activity Counseling Trial]] | | [[Effects Of Physical Activity Counseling In Primary Care: The Activity Counseling Trial]] | ||
|- | |- | ||
| ACT | | [[ACT]] | ||
| [[Angioplasty Compliance Trial]] | | [[Angioplasty Compliance Trial]] | ||
|- | |- | ||
| ACTION | | [[ACTION]] | ||
| [[Coronary Disease Trial Investigating Outcome With Nifedipine Gits]] | | [[Coronary Disease Trial Investigating Outcome With Nifedipine Gits]] | ||
|- | |- | ||
| ACTION | | [[ACTION]] | ||
| [[Actinomycin Eluting Stent Improves Outcomes By Reducing Neointimal Hyperplasia]] | | [[Actinomycin Eluting Stent Improves Outcomes By Reducing Neointimal Hyperplasia]] | ||
|- | |- | ||
| ACTIV in CHF | | [[ACTIV in CHF]] | ||
| [[Acute And Chronic Therapeutic Impact Of A Vasopressin 2 Antagonist (Tolvaptan) In Congestive Heart Failure]] | | [[Acute And Chronic Therapeutic Impact Of A Vasopressin 2 Antagonist (Tolvaptan) In Congestive Heart Failure]] | ||
|- | |- | ||
| ACTIVATE | | [[ACTIVATE]] | ||
| [[Acat Inhibition On The Progression Of Coronary Atherosclerosis]] | | [[Acat Inhibition On The Progression Of Coronary Atherosclerosis]] | ||
|- | |- | ||
| ACTIVE A | | [[ACTIVE A]] | ||
| [[The Atrial Fibrillation Clopidogrel Trial With Irbesartan For Prevention Of Vascular Events]] | | [[The Atrial Fibrillation Clopidogrel Trial With Irbesartan For Prevention Of Vascular Events]] | ||
|- | |- | ||
| ACTIVE W | | [[ACTIVE W]] | ||
| [[Atrial Fibrillation Clopidogrel Trial With Irbesartan For Prevention Of Vascular Events]] | | [[Atrial Fibrillation Clopidogrel Trial With Irbesartan For Prevention Of Vascular Events]] | ||
|- | |- | ||
| ACUITY | | [[ACUITY]] | ||
| [[Acute Catheterization And Urgent Intervention Triage Strategy Trial]] | | [[Acute Catheterization And Urgent Intervention Triage Strategy Trial]] | ||
|- | |- | ||
| ACUITY PCI: 30-day and 1-Year Results | | [[ACUITY PCI: 30-day and 1-Year Results]] | ||
| [[Acute Catheterization And Urgent Intervention Triage Strategy Trial - Pci Subgroup: 30-Day And 1-Year Results]] | | [[Acute Catheterization And Urgent Intervention Triage Strategy Trial - Pci Subgroup: 30-Day And 1-Year Results]] | ||
|- | |- | ||
| ACUITY Timing Trial | | [[ACUITY Timing Trial]] | ||
| [[Acute Catheterization And Urgent Intervention Triage Strategy Timing Trial]] | | [[Acute Catheterization And Urgent Intervention Triage Strategy Timing Trial]] | ||
|- | |- | ||
| ACUTE | | [[ACUTE]] | ||
| [[Assessment Of Cardioversion Using Transesophageal Echocardiography]] | | [[Assessment Of Cardioversion Using Transesophageal Echocardiography]] | ||
|- | |- | ||
| ACUTE | | [[ACUTE]] | ||
| [[Analysis Of Coronary Ultrasound Thrombolysis Endpoints In Acute Myocardial Infarction]] | | [[Analysis Of Coronary Ultrasound Thrombolysis Endpoints In Acute Myocardial Infarction]] | ||
|- | |- | ||
| ACUTE II | | [[ACUTE II]] | ||
| [[Assessment Of Cardioversion Using Transesophageal Echocardiography]] | | [[Assessment Of Cardioversion Using Transesophageal Echocardiography]] | ||
|- | |- | ||
| ADAM | | [[ADAM]] | ||
| [[Aneurysm Detection And Management Veterans Affairs Cooperative Study]] | | [[Aneurysm Detection And Management Veterans Affairs Cooperative Study]] | ||
|- | |- | ||
| ADAM | | [[ADAM]] | ||
| [[Amsterdam Duration Of Antiretroviral Medication Study]] | | [[Amsterdam Duration Of Antiretroviral Medication Study]] | ||
|- | |- | ||
| ADAPT | | [[ADAPT]] | ||
| [[Alzheimer's Disease Anti-Inflammatory Prevention Trial]] | | [[Alzheimer's Disease Anti-Inflammatory Prevention Trial]] | ||
|- | |- | ||
| ADCS | | [[ADCS]] | ||
| [[Alzheimer's Disease Cooperative Study]] | | [[Alzheimer's Disease Cooperative Study]] | ||
|- | |- | ||
| ADEMEX | | [[ADEMEX]] | ||
| [[Adequacy Of Peritoneal Dialysis In Mexico]] | | [[Adequacy Of Peritoneal Dialysis In Mexico]] | ||
|- | |- | ||
| ADEPT | | [[ADEPT]] | ||
| [[Advanced Elements Of Pacing Trial]] | | [[Advanced Elements Of Pacing Trial]] | ||
|- | |- | ||
| ADIOS | | [[ADIOS]] | ||
| [[Antiarrhythmic Drug Improve Outcome Study]] | | [[Antiarrhythmic Drug Improve Outcome Study]] | ||
|- | |- | ||
| ADMIRAL | | [[ADMIRAL]] | ||
| [[Platelet Glycoprotein IIb/IIia Inhibition With Coronary Stenting For Acute Myocardial Infarction]] | | [[Platelet Glycoprotein IIb/IIia Inhibition With Coronary Stenting For Acute Myocardial Infarction]] | ||
|- | |- | ||
| ADMIRAL | | [[ADMIRAL]] | ||
| [[Abciximab Before Direct Angioplasty And Stenting In Myocardial Infarction Regarding Acute And Long-Term Followup]] | | [[Abciximab Before Direct Angioplasty And Stenting In Myocardial Infarction Regarding Acute And Long-Term Followup]] | ||
|- | |- | ||
| ADMIT | | [[ADMIT]] | ||
| [[Arterial Disease Multiple Intervention Trial]] | | [[Arterial Disease Multiple Intervention Trial]] | ||
|- | |- | ||
| ADONIS | | [[ADONIS]] | ||
| [[Aspirin Dose Optimized In Noncardioembolic Ischemic Stroke]] | | [[Aspirin Dose Optimized In Noncardioembolic Ischemic Stroke]] | ||
|- | |- | ||
| ADOPT | | [[ADOPT]] | ||
| [[Atrial Dynamic Overdrive Pacing Trial]] | | [[Atrial Dynamic Overdrive Pacing Trial]] | ||
|- | |- | ||
| ADOPT | | [[ADOPT]] | ||
| [[A Diabetes Outcome Progression Trial]] | | [[A Diabetes Outcome Progression Trial]] | ||
|- | |- | ||
| ADOPT-A | | [[ADOPT-A]] | ||
| [[Atrial Dynamic Overdrive Pacing Trial-A]] | | [[Atrial Dynamic Overdrive Pacing Trial-A]] | ||
|- | |- | ||
| ADVANCE | | [[ADVANCE]] | ||
| [[A Randomized Comparison Of The Value Of Additional Stenting After Optimal Balloon Angioplasty For Long Coronary Lesions]] | | [[A Randomized Comparison Of The Value Of Additional Stenting After Optimal Balloon Angioplasty For Long Coronary Lesions]] | ||
|- | |- | ||
| ADVANCE | | [[ADVANCE]] | ||
| [[Additive Value Of Tirofiban Administered With The High-Dose Bolus In The Prevention Of Ischemic Complications During High-Risk Coronary Angioplasty]] | | [[Additive Value Of Tirofiban Administered With The High-Dose Bolus In The Prevention Of Ischemic Complications During High-Risk Coronary Angioplasty]] | ||
|- | |- | ||
| ADVANCE | | [[ADVANCE]] | ||
| [[Action In Diabetes And Vascular Disease: Preterax And Diamicron Modified Release Controlled Evaluation]] | | [[Action In Diabetes And Vascular Disease: Preterax And Diamicron Modified Release Controlled Evaluation]] | ||
|- | |- | ||
| ADVANCE | | [[ADVANCE]] | ||
| [[A Dosing Evaluation Of A Vasopressin Antagonist In Chf Patients Undergoing Exercise]] | | [[A Dosing Evaluation Of A Vasopressin Antagonist In Chf Patients Undergoing Exercise]] | ||
|- | |- | ||
| ADVENT | | [[ADVENT]] | ||
| [[Assessment Of Diabetes Control And Evaluation Of The Efficacy Of Niaspan Trial]] | | [[Assessment Of Diabetes Control And Evaluation Of The Efficacy Of Niaspan Trial]] | ||
|- | |- | ||
| AEGIS | | [[AEGIS]] | ||
| [[Alternative Graft Investigational Study]] | | [[Alternative Graft Investigational Study]] | ||
|- | |- | ||
| A-F | | [[A-F]] | ||
| [[Vascular Protection In High-Risk Non–St-Elevation Acute Coronary Syndromes: The Angioplasty Balloon-Associated Coronary Debris And The Ez Filterwire]] | | [[Vascular Protection In High-Risk Non–St-Elevation Acute Coronary Syndromes: The Angioplasty Balloon-Associated Coronary Debris And The Ez Filterwire]] | ||
|- | |- | ||
| AFASAK | | [[AFASAK]] | ||
| [[Atrial Fibrillation, Aspirin, Antikoagulation]] | | [[Atrial Fibrillation, Aspirin, Antikoagulation]] | ||
|- | |- | ||
| AFASAK-2 | | [[AFASAK-2]] | ||
| [[Second Copenhagen Atrial Fibrillation, Aspirin, And Anticoagulation Study]] | | [[Second Copenhagen Atrial Fibrillation, Aspirin, And Anticoagulation Study]] | ||
|- | |- | ||
| AFCAPS | | [[AFCAPS]] | ||
| [[Air Force Coronary Atherosclerosis Prevention Study]] | | [[Air Force Coronary Atherosclerosis Prevention Study]] | ||
|- | |- | ||
| AFCAPS/TEXCAPS | | [[AFCAPS/TEXCAPS]] | ||
| [[Air Force Texas Coronary Atherosclerosis Prevention Study]] | | [[Air Force Texas Coronary Atherosclerosis Prevention Study]] | ||
|- | |- | ||
| AF-CHF | | [[AF-CHF]] | ||
| [[Atrial Fibrillation And Congestive Heart Failure]] | | [[Atrial Fibrillation And Congestive Heart Failure]] | ||
|- | |- | ||
| AFFIRM | | [[AFFIRM]] | ||
| [[Atrial Fibrillation Follow-Up Investigation Of Rhythm Management]] | | [[Atrial Fibrillation Follow-Up Investigation Of Rhythm Management]] | ||
|- | |- | ||
| AFIB | | [[AFIB]] | ||
| [[Atrial Fibrillation Investigation With Bidisomide]] | | [[Atrial Fibrillation Investigation With Bidisomide]] | ||
|- | |- | ||
| AFREGS | | [[AFREGS]] | ||
| [[Armed Forces Regression Study]] | | [[Armed Forces Regression Study]] | ||
|- | |- | ||
| AGENT | | [[AGENT]] | ||
| [[Angiogenic Gene Therapy]] | | [[Angiogenic Gene Therapy]] | ||
|- | |- | ||
| AGENT-2 | | [[AGENT-2]] | ||
| [[Angiogenic Gene Therapy Trial]] | | [[Angiogenic Gene Therapy Trial 2]] | ||
|- | |- | ||
| AGENT-3 | | [[AGENT-3]] | ||
| [[A Multicenter, Prospective, Randomized Trial Of Intracoronary Administration Of Ad5Fgf-4 In Patients With No Revascularization Options]] | | [[A Multicenter, Prospective, Randomized Trial Of Intracoronary Administration Of Ad5Fgf-4 In Patients With No Revascularization Options]] | ||
|- | |- | ||
| AGIS | | [[AGIS]] | ||
| [[Advanced Glaucoma Intervention Study]] | | [[Advanced Glaucoma Intervention Study]] | ||
|- | |- | ||
| A-HeFT | | [[A-HeFT]] | ||
| [[African-American Heart Failure Trial]] | | [[African-American Heart Failure Trial]] | ||
|- | |- | ||
| AiMI | | [[AiMI]] | ||
| [[A Prospective, Randomized, Controlled Trial Of Thrombectomy With The Angiojet In Acute Myocardial Infarction]] | | [[A Prospective, Randomized, Controlled Trial Of Thrombectomy With The Angiojet In Acute Myocardial Infarction]] | ||
|- | |- | ||
| AIMS | | [[AIMS]] | ||
| [[Apsac Intervention Mortality Study]] | | [[Apsac Intervention Mortality Study]] | ||
|- | |- | ||
| AIR | | [[AIR]] | ||
| [[Aerosolized Iloprost Randomized Placebo-Controlled Study]] | | [[Aerosolized Iloprost Randomized Placebo-Controlled Study]] | ||
|- | |- | ||
| Air PAMI | | [[Air PAMI]] | ||
| [[The Air Primary Angioplasty In Myocardial Infarction Study]] | | [[The Air Primary Angioplasty In Myocardial Infarction Study]] | ||
|- | |- | ||
| AIRCRAFT | | [[AIRCRAFT]] | ||
| [[The Australian Intervention Randomized Control Of Rate In Atrial Fibrillation Trial]] | | [[The Australian Intervention Randomized Control Of Rate In Atrial Fibrillation Trial]] | ||
|- | |- | ||
| AIRE | | [[AIRE]] | ||
| [[Acute Infarction Ramipril Efficacy Study]] | | [[Acute Infarction Ramipril Efficacy Study]] | ||
|- | |- | ||
| AIST-ASH | | [[AIST-ASH]] | ||
| [[Acute Ischemic Stroke Trial: Oral Aspirin Vs Intravenous Heparin On Stroke Progression]] | | [[Acute Ischemic Stroke Trial: Oral Aspirin Vs Intravenous Heparin On Stroke Progression]] | ||
|- | |- | ||
| ALBION | | [[ALBION]] | ||
| [[Assessment Of The Best Loading Dose Of Clopidogrel To Blunt Platelet Activation, Inflammation, And On-Going Necrosis]] | | [[Assessment Of The Best Loading Dose Of Clopidogrel To Blunt Platelet Activation, Inflammation, And On-Going Necrosis]] | ||
|- | |- | ||
| ALERT | | [[ALERT]] | ||
| [[Assessment Of Lescol In Renal Transplantation]] | | [[Assessment Of Lescol In Renal Transplantation]] | ||
|- | |- | ||
| ALERT | | [[ALERT]] | ||
| [[Adjunctive Lamictal In Epilepsy And Response To Treatment]] | | [[Adjunctive Lamictal In Epilepsy And Response To Treatment]] | ||
|- | |- | ||
| ALIVE | | [[ALIVE]] | ||
| [[Azimilide Post-Infarct Survival Evaluation]] | | [[Azimilide Post-Infarct Survival Evaluation]] | ||
|- | |- | ||
| ALIVE | | [[ALIVE]] | ||
| [[Adenosine Lidocaine Infarct Zone Viability Enhancement]] | | [[Adenosine Lidocaine Infarct Zone Viability Enhancement]] | ||
|- | |- | ||
| ALIVE (amio vs. lidocaine | | [[ALIVE (amio vs. lidocaine]] | ||
| [[Amiodarone As Compared With Lidocaine For Shock-Resistant Ventricular Fibrillation]] | | [[Amiodarone As Compared With Lidocaine For Shock-Resistant Ventricular Fibrillation]] | ||
|- | |- | ||
| ALKK | | [[ALKK]] | ||
| [[Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte]] | | [[Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte]] | ||
|- | |- | ||
| ALLAY | | [[ALLAY]] | ||
| [[Aliskiren In Left Ventricular Hypertrophy]] | | [[Aliskiren In Left Ventricular Hypertrophy]] | ||
|- | |- | ||
| [[ALLHAT]] | |||
| [[ | |||
| [[Antihypertensive And Lipid-Lowering Treatment To Prevent Heart Attack Trial]] | | [[Antihypertensive And Lipid-Lowering Treatment To Prevent Heart Attack Trial]] | ||
|- | |- | ||
| ALLIANCE | | [[ALLIANCE]] | ||
| [[Aggressive Lipid-Lowering Initiation Abates New Cardiac Events]] | | [[Aggressive Lipid-Lowering Initiation Abates New Cardiac Events]] | ||
|- | |- | ||
| ALOFT | | [[ALOFT]] | ||
| [[Aliskiren Observations Of Heart Failure Treatment]] | | [[Aliskiren Observations Of Heart Failure Treatment]] | ||
|- | |- | ||
| ALPHA | | [[ALPHA]] | ||
| [[T-Wave Alternans In Patients With Heart Failure]] | | [[T-Wave Alternans In Patients With Heart Failure]] | ||
|- | |- | ||
| ALPHABET | | [[ALPHABET]] | ||
| [[Effects Of Beraprost Sodium, An Oral Prostacyclin Analogue, In Patients With Pulmonary Arterial Hypertension: A Randomized, Double-Blind, Placebo-Controlled Trial]] | | [[Effects Of Beraprost Sodium, An Oral Prostacyclin Analogue, In Patients With Pulmonary Arterial Hypertension: A Randomized, Double-Blind, Placebo-Controlled Trial]] | ||
|- | |- | ||
| ALTS | | [[ALTS]] | ||
| [[Ascus/Lsil Triage Study ]] | | [[Ascus/Lsil Triage Study ]] | ||
|- | |- | ||
| AMADEUS | | [[AMADEUS]] | ||
| [[Comparison Of Idraparinux With Vitamin K Antagonists For Prevention Of Thromboembolism In Patients With Atrial Fibrillation]] | | [[Comparison Of Idraparinux With Vitamin K Antagonists For Prevention Of Thromboembolism In Patients With Atrial Fibrillation]] | ||
|- | |- | ||
| AMAZE | | [[AMAZE]] | ||
| [[A Multicenter Trial Using-Zestril Versus To Evaluate The Effects On Lowering Blood Pressure ]] | | [[A Multicenter Trial Using-Zestril Versus To Evaluate The Effects On Lowering Blood Pressure ]] | ||
|- | |- | ||
| AMEthyst | | [[AMEthyst]] | ||
| [[Assessment Of The Medtronic Ave Interceptor Saphenous Vein Graft Filter System]] | | [[Assessment Of The Medtronic Ave Interceptor Saphenous Vein Graft Filter System]] | ||
|- | |- | ||
| AMIGO | | [[AMIGO]] | ||
| [[Atherectomy And Multilink Stenting Improves Gain In Outcome Trial]] | | [[Atherectomy And Multilink Stenting Improves Gain In Outcome Trial]] | ||
|- | |- | ||
| AMIGO | | [[AMIGO]] | ||
| [[Ac2993: Diabetes Management For Improving Glucose Outcome]] | | [[Ac2993: Diabetes Management For Improving Glucose Outcome]] | ||
|- | |- | ||
| AMIHOT | | [[AMIHOT]] | ||
| [[Acute Myocardial Infarction With Hyperoxemic Therapy]] | | [[Acute Myocardial Infarction With Hyperoxemic Therapy]] | ||
|- | |- | ||
| AMIHOT II | | [[AMIHOT II]] | ||
| [[Acute Myocardial Infarction With Hyperoxemic Therapy II]] | | [[Acute Myocardial Infarction With Hyperoxemic Therapy II]] | ||
|- | |- | ||
| AMIOVIRT | | [[AMIOVIRT]] | ||
| [[Amiodarone Versus Implantable Defibrillator In Patients With Nonischemic Cardiomyopathy And Asymptomatic Nonsustained Ventricular Tachycardia Study]] | | [[Amiodarone Versus Implantable Defibrillator In Patients With Nonischemic Cardiomyopathy And Asymptomatic Nonsustained Ventricular Tachycardia Study]] | ||
|- | |- | ||
| [[AMISTAD I]] | |||
| [[ | |||
| [[Acute Myocardial Infarction Study Of Adenosine Trial]] | | [[Acute Myocardial Infarction Study Of Adenosine Trial]] | ||
|- | |- | ||
| AMISTAD II | | [[AMISTAD II]] | ||
| [[Acute Myocardial Infarction Study Of Adenosine II]] | | [[Acute Myocardial Infarction Study Of Adenosine II]] | ||
|- | |- | ||
| AMRO | | [[AMRO]] | ||
| [[Amsterdam-Rotterdam Trial]] | | [[Amsterdam-Rotterdam Trial]] | ||
|- | |- | ||
| ANBP2 | | [[ANBP2]] | ||
| [[Australian National Blood Pressure Study Group]] | | [[Australian National Blood Pressure Study Group]] | ||
|- | |- | ||
| ANDROMEDA | | [[ANDROMEDA]] | ||
| [[Increased Mortality After Dronedarone Therapy For Severe Heart Failure]] | | [[Increased Mortality After Dronedarone Therapy For Severe Heart Failure]] | ||
|- | |- | ||
| ANTHEM–TIMI-32 | | [[ANTHEM–TIMI-32]] | ||
| [[Anticoagulation With Rnapc2 To Eliminate Mace/Timi 32]] | | [[Anticoagulation With Rnapc2 To Eliminate Mace/Timi 32]] | ||
|- | |- | ||
| ANTIBIO | | [[ANTIBIO]] | ||
| [[Antibiotic Therapy After An Acute Myocardial Infarction]] | | [[Antibiotic Therapy After An Acute Myocardial Infarction]] | ||
|- | |- | ||
| ANZ-Carvedilol | | [[ANZ-Carvedilol]] | ||
| [[Australia-New Zealand Heart Failure Research Collaborative Group Carvedilol Trial]] | | [[Australia-New Zealand Heart Failure Research Collaborative Group Carvedilol Trial]] | ||
|- | |- | ||
| APAF | | [[APAF]] | ||
| [[Ablation For Paroxysmal Atrial Fibrillation (Apaf) Trial]] | | [[Ablation For Paroxysmal Atrial Fibrillation (Apaf) Trial]] | ||
|- | |- | ||
| APASS | | [[APASS]] | ||
| [[Antiphospholipid Antibody Stroke Study]] | | [[Antiphospholipid Antibody Stroke Study]] | ||
|- | |- | ||
| APC | | [[APC]] | ||
| [[Adenoma Prevention With Celecoxib]] | | [[Adenoma Prevention With Celecoxib]] | ||
|- | |- | ||
| APEX AMI | | [[APEX AMI]] | ||
| [[Assessment Of Pexelizumab In Acute Myocardial Infarction]] | | [[Assessment Of Pexelizumab In Acute Myocardial Infarction]] | ||
|- | |- | ||
| APLAUSE | | [[APLAUSE]] | ||
| [[Anti-Platelet Treatment After Intravascular Ultrasound Guided Optimal Stent Expansion]] | | [[Anti-Platelet Treatment After Intravascular Ultrasound Guided Optimal Stent Expansion]] | ||
|- | |- | ||
| APOCARD | | [[APOCARD]] | ||
| [[Imaging In Cardiac Transplant Patients]] | | [[Imaging In Cardiac Transplant Patients]] | ||
|- | |- | ||
| APPRAISE-1 | | [[APPRAISE-1]] | ||
| [[Safety Of The Factor Xa Inhibitor, Apixaban, In Combination With Antiplatelet Therapy After Acute Coronary Syndromes: A Dose-Guiding Trial]] | | [[Safety Of The Factor Xa Inhibitor, Apixaban, In Combination With Antiplatelet Therapy After Acute Coronary Syndromes: A Dose-Guiding Trial]] | ||
|- | |- | ||
| APPROACH | | [[APPROACH]] | ||
| [[Assessment On The Prevention Of Progression By Rosiglitazone On Atherosclerosis In Diabetes Patients With Cardiovascular History]] | | [[Assessment On The Prevention Of Progression By Rosiglitazone On Atherosclerosis In Diabetes Patients With Cardiovascular History]] | ||
|- | |- | ||
| APRES | | [[APRES]] | ||
| [[Angiotensin-Converting Enzyme Inhibition Post Revascularization Study]] | | [[Angiotensin-Converting Enzyme Inhibition Post Revascularization Study]] | ||
|- | |- | ||
| APRICOT | | [[APRICOT]] | ||
| [[Antithrombotics In The Prevention Of Reocclusion In Coronary Thrombolysis]] | | [[Antithrombotics In The Prevention Of Reocclusion In Coronary Thrombolysis]] | ||
|- | |- | ||
| APRICOT-2 | | [[APRICOT-2]] | ||
| [[Antithrombotics In The Prevention Of Reocclusion In Coronary Thrombolysis-2]] | | [[Antithrombotics In The Prevention Of Reocclusion In Coronary Thrombolysis-2]] | ||
|- | |- | ||
| ARBITER 2 | | [[ARBITER 2]] | ||
| [[Arterial Biology For The Investigation Of The Treatment Effects Of Reducing Cholesterol 2]] | | [[Arterial Biology For The Investigation Of The Treatment Effects Of Reducing Cholesterol 2]] | ||
|- | |- | ||
| ARCH | | [[ARCH]] | ||
| [[Amiodarone Reduction In Coronary Heart Trial]] | | [[Amiodarone Reduction In Coronary Heart Trial]] | ||
|- | |- | ||
| ARCHeR | | [[ARCHeR]] | ||
| [[For Revascularization Of Carotids In High-Risk Patients]] | | [[For Revascularization Of Carotids In High-Risk Patients]] | ||
|- | |- | ||
| AREDS | | [[AREDS]] | ||
| [[Age-Related Eye Disease Study]] | | [[Age-Related Eye Disease Study]] | ||
|- | |- | ||
| ARG-911 | | [[ARG-911]] | ||
| [[Argatroban-911]] | | [[Argatroban-911]] | ||
|- | |- | ||
| ARG-915 | | [[ARG-915]] | ||
| [[Argatroban-915]] | | [[Argatroban-915]] | ||
|- | |- | ||
| ARGAMI-2 | | [[ARGAMI-2]] | ||
| [[Argatroban For Acute Myocardial Infarction]] | | [[Argatroban For Acute Myocardial Infarction]] | ||
|- | |- | ||
| ARIC | | [[ARIC]] | ||
| [[Atherosclerosis Risk In Communities]] | | [[Atherosclerosis Risk In Communities]] | ||
|- | |- | ||
| ARIES 1 and 2 | | [[ARIES 1 and 2]] | ||
| [[Ambrisentan In Pulmonary Arterial Hypertension Efficacy Study 1 And 2]] | | [[Ambrisentan In Pulmonary Arterial Hypertension Efficacy Study 1 And 2]] | ||
|- | |- | ||
| ARISE | | [[ARISE]] | ||
| [[Aggressive Reduction Of Inflammation Stops Events]] | | [[Aggressive Reduction Of Inflammation Stops Events]] | ||
|- | |- | ||
| ARMS | | [[ARMS]] | ||
| [[Apsac Reocclusion Multicenter Study]] | | [[Apsac Reocclusion Multicenter Study]] | ||
|- | |- | ||
| ARMYDA | | [[ARMYDA]] | ||
| [[Atorvastatin For Reduction Of Myocardial Damage During Angioplasty]] | | [[Atorvastatin For Reduction Of Myocardial Damage During Angioplasty]] | ||
|- | |- | ||
| ARMYDA-2 | | [[ARMYDA-2]] | ||
| [[Antiplatelet Therapy For Reduction Of Myocardial Damage During Angioplasty | | [[Antiplatelet Therapy For Reduction Of Myocardial Damage During Angioplasty 2]] | ||
|- | |- | ||
| ARMYDA-3 | | [[ARMYDA-3]] | ||
| [[ | | [[Antiplatelet Therapy For Reduction Of Myocardial Damage During Angioplasty 3]] | ||
|- | |- | ||
| ARMYDA-4 | | [[ARMYDA-4]] | ||
| [[Antiplatelet Therapy For Reduction Of Myocardial Damage During Angioplasty 4]] | | [[Antiplatelet Therapy For Reduction Of Myocardial Damage During Angioplasty 4]] | ||
|- | |- | ||
| ARMYDA-5 | | [[ARMYDA-5]] | ||
| [[Antiplatelet Therapy For Reduction Of Myocardial Damage During Angioplasty 5]] | | [[Antiplatelet Therapy For Reduction Of Myocardial Damage During Angioplasty 5]] | ||
|- | |- | ||
| ARMYDA-ACS | | [[ARMYDA-ACS]] | ||
| [[Atorvastatin For Reduction Of Myocardial Damage During Angioplasty-Acute Coronary Syndromes]] | | [[Atorvastatin For Reduction Of Myocardial Damage During Angioplasty-Acute Coronary Syndromes]] | ||
|- | |- | ||
| ARMYDA-RECAPTURE | | [[ARMYDA-RECAPTURE]] | ||
| [[Atorvastatin For Reduction Of Myocardial Damage During Angioplasty]] | | [[Atorvastatin For Reduction Of Myocardial Damage During Angioplasty-Recapture]] | ||
|- | |- | ||
| ARMYDA-RELOAD | | [[ARMYDA-RELOAD]] | ||
| [[Antiplatelet Therapy For Reduction Of Myocardial Damage During Angioplasty-Reload]] | | [[Antiplatelet Therapy For Reduction Of Myocardial Damage During Angioplasty-Reload]] | ||
|- | |- | ||
| ARPEGGIO | | [[ARPEGGIO]] | ||
| [[Rimonabant Improves Glycemic Control In Insulin-Treated Type 2 Diabetes]] | | [[Rimonabant Improves Glycemic Control In Insulin-Treated Type 2 Diabetes]] | ||
|- | |- | ||
| ARREST | | [[ARREST]] | ||
| [[Amiodarone For Resuscitation After Out-Of-Hospital Cardiac Arrest Due To Ventricular Fibrillation]] | | [[Amiodarone For Resuscitation After Out-Of-Hospital Cardiac Arrest Due To Ventricular Fibrillation]] | ||
|- | |- | ||
| ARREST | | [[ARREST]] | ||
| [[Angiorad Radiation For Restenosis]] | | [[Angiorad Radiation For Restenosis]] | ||
|- | |- | ||
| ARTIST | | [[ARTIST]] | ||
| [[Angioplasty Versus Rotational Atherectomy For Treatment Of Diffuse In-Stent Restenosis Trial]] | | [[Angioplasty Versus Rotational Atherectomy For Treatment Of Diffuse In-Stent Restenosis Trial]] | ||
|- | |- | ||
| ARTISTIC | | [[ARTISTIC]] | ||
| [[Angiorad Radiation Therapy For In-Stent Restenosis Intracoronary]] | | [[Angiorad Radiation Therapy For In-Stent Restenosis Intracoronary]] | ||
|- | |- | ||
| ARTS | | [[ARTS]] | ||
| [[Arterial Revascularization Therapies Study]] | | [[Arterial Revascularization Therapies Study]] | ||
|- | |- | ||
| ARTS I - Five year follow-up | | [[ARTS I - Five year follow-up]] | ||
| [[Five Year Clinical Follow-Up Of The Arterial Revascularisation Therapy Study]] | | [[Five Year Clinical Follow-Up Of The Arterial Revascularisation Therapy Study]] | ||
|- | |- | ||
| ARTS-II | | [[ARTS-II]] | ||
| [[Arterial Revascularization Therapies Study Part II: Sirolimus-Eluting Stents For The Treatment Of Patients With Multivessel De Novo Coronary Artery Lesions]] | | [[Arterial Revascularization Therapies Study Part II: Sirolimus-Eluting Stents For The Treatment Of Patients With Multivessel De Novo Coronary Artery Lesions]] | ||
|- | |- | ||
| ASAP | | [[ASAP]] | ||
| [[Effect Of Aggressive Versus Conventional Lipid Lowering On Atherosclerosis Progression In Familial Hypercholesterolemia]] | | [[Effect Of Aggressive Versus Conventional Lipid Lowering On Atherosclerosis Progression In Familial Hypercholesterolemia]] | ||
|- | |- | ||
| ASAP | | [[ASAP]] | ||
| [[Azimilide Supraventricular Arrhythmia Program ]] | | [[Azimilide Supraventricular Arrhythmia Program ]] | ||
|- | |- | ||
| ASCENT | | [[ASCENT]] | ||
| [[Acs Stent Clinical Equivalence In De Novo Lesions Trial]] | | [[Acs Stent Clinical Equivalence In De Novo Lesions Trial]] | ||
|- | |- | ||
| ASCOT | | [[ASCOT]] | ||
| [[Anglo-Scandinavian Cardiac Outcome Trial]] | | [[Anglo-Scandinavian Cardiac Outcome Trial]] | ||
|- | |- | ||
| ASCOT - Blood Pressure Arm | | [[ASCOT - Blood Pressure Arm]] | ||
| [[ Anglo-Scandinavian Cardiac Outcomes Trial: Blood Pressure-Lowering Arm]] | | [[ Anglo-Scandinavian Cardiac Outcomes Trial: Blood Pressure-Lowering Arm]] | ||
|- | |- | ||
| ASCOT - Lipid Arm | | [[ASCOT - Lipid Arm]] | ||
| [[ Anglo-Scandinavian Cardiac Outcomes Trial]] | | [[ Anglo-Scandinavian Cardiac Outcomes Trial]] | ||
|- | |- | ||
| ASFAST | | [[ASFAST]] | ||
| [[Atherosclerosis And Folic Acid Supplementation Trial]] | | [[Atherosclerosis And Folic Acid Supplementation Trial]] | ||
|- | |- | ||
| ASIS | | [[ASIS]] | ||
| [[Angina And Silent Ischemia Study]] | | [[Angina And Silent Ischemia Study]] | ||
|- | |- | ||
| ASPAC | | [[ASPAC]] | ||
| [[Asian-Pacific Collaboration On Chd Risk Factor Intervention]] | | [[Asian-Pacific Collaboration On Chd Risk Factor Intervention]] | ||
|- | |- | ||
| ASPECT | | [[ASPECT]] | ||
| [[Anticoagulants In Secondary Prevention Of Events In Coronary Thrombosis]] | | [[Anticoagulants In Secondary Prevention Of Events In Coronary Thrombosis]] | ||
|- | |- | ||
| ASPECT | | [[ASPECT]] | ||
| [[Asian Paclitaxel-Eluting Stent Clinical Trial]] | | [[Asian Paclitaxel-Eluting Stent Clinical Trial]] | ||
|- | |- | ||
| [[ASPECT-2]] | |||
| [[ | |||
| [[Aspirin And Coumadin After Acute Coronary Syndromes (The Aspect-2) Study: A Randomised Controlled Trial.]] | | [[Aspirin And Coumadin After Acute Coronary Syndromes (The Aspect-2) Study: A Randomised Controlled Trial.]] | ||
|- | |- | ||
| ASPEN | | [[ASPEN]] | ||
| [[Atorvastatin Study For The Prevention Of Endpoints For Patients With Niddm]] | | [[Atorvastatin Study For The Prevention Of Endpoints For Patients With Niddm]] | ||
|- | |- | ||
| ASPIRE | | [[ASPIRE]] | ||
| [[Arixtra Study In Percutaneous Coronary Intervention: A Randomized Evaluation]] | | [[Arixtra Study In Percutaneous Coronary Intervention: A Randomized Evaluation]] | ||
|- | |- | ||
| [[ASSENT 3]] | |||
| [[ | |||
| [[The Assessment Of The Safety And Efficacy Of A New Thrombolytic Regimen (Assent)-3 Investigators. Efficacy And Safety Of Tenecteplase In Combination With Enoxaparin, Abciximab, Or Unfractionated Heparin: The Assent-3 Randomized Trial In Acute Mi]] | | [[The Assessment Of The Safety And Efficacy Of A New Thrombolytic Regimen (Assent)-3 Investigators. Efficacy And Safety Of Tenecteplase In Combination With Enoxaparin, Abciximab, Or Unfractionated Heparin: The Assent-3 Randomized Trial In Acute Mi]] | ||
|- | |- | ||
| ASSENT 3 PLUS | | [[ASSENT 3 PLUS]] | ||
| [[Assessment Of The Safety And Efficacy Of A New Thrombolytic Regimen]] | | [[Assessment Of The Safety And Efficacy Of A New Thrombolytic Regimen-3]] | ||
|- | |- | ||
| ASSENT-1 | | [[ASSENT-1]] | ||
| [[Assessment Of The Safety Of A New Thrombolytic: Tnk-Tpa]] | | [[Assessment Of The Safety and Efficacy Of A New Thrombolytic: Tnk-Tpa]] | ||
|- | |- | ||
| ASSENT-2 | | [[ASSENT-2]] | ||
| [[Assessment Of The Safety And Efficacy Of A New Thrombolytic: Tnk-Tpa]] | | [[Assessment Of The Safety And Efficacy Of A New Thrombolytic: Tnk-Tpa-2]] | ||
|- | |- | ||
| ASSENT-4 PCI | | [[ASSENT-4 PCI]] | ||
| [[Assessment Of The Safety And Efficacy Of A New Treatment Strategy For Acute Myocardial Infarction]] | | [[Assessment Of The Safety And Efficacy Of A New Treatment Strategy For Acute Myocardial Infarction]] | ||
|- | |- | ||
| ASSERT | | [[ASSERT]] | ||
| [[Aortic Stentless Versus Stented Valve Assessed By Echocardiography Randomized Trial]] | | [[Aortic Stentless Versus Stented Valve Assessed By Echocardiography Randomized Trial]] | ||
|- | |- | ||
| ASSET | | [[ASSET]] | ||
| [[Anglo-Scandinavian Study Of Early Thrombolysis]] | | [[Anglo-Scandinavian Study Of Early Thrombolysis]] | ||
|- | |- | ||
| ASSIST | | [[ASSIST]] | ||
| [[Assessment Of Implementation Strategies]] | | [[Assessment Of Implementation Strategies]] | ||
|- | |- | ||
| ASSIST | | [[ASSIST]] | ||
| [[A Stop Smoking In Schools Trial]] | | [[A Stop Smoking In Schools Trial]] | ||
|- | |- | ||
| ASSURE | | [[ASSURE]] | ||
| [[Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit Of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter Defibrillator Implantations]] | | [[Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit Of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter Defibrillator Implantations]] | ||
|- | |- | ||
| ASTAMI | | [[ASTAMI]] | ||
| [[Astami]] | | [[Astami]] | ||
|- | |- | ||
| ASTEROID | | [[ASTEROID]] | ||
| [[A Study To Evaluate The Effect Of Rosuvastatin On Intravascular Ultrasound-Derived Coronary Atheroma Burden]] | | [[A Study To Evaluate The Effect Of Rosuvastatin On Intravascular Ultrasound-Derived Coronary Atheroma Burden]] | ||
|- | |- | ||
| ASTIS | | [[ASTIS]] | ||
| [[Autologous Stem Cell Transplantation International Scleroderma Trial]] | | [[Autologous Stem Cell Transplantation International Scleroderma Trial]] | ||
|- | |- | ||
| ASTRAL | | [[ASTRAL]] | ||
| [[Angioplasty And Stenting For Renal Artery Lesions]] | | [[Angioplasty And Stenting For Renal Artery Lesions]] | ||
|- | |- | ||
| ASTRID | | [[ASTRID]] | ||
| [[Atrial Sensing Trial To Prevent Inappropriate Detections]] | | [[Atrial Sensing Trial To Prevent Inappropriate Detections]] | ||
|- | |- | ||
| ASTRONAUT | | [[ASTRONAUT]] | ||
| [[Acid Suppression Trial: Ranitidine Zantac Versus Omeprazole]] | | [[Acid Suppression Trial: Ranitidine Zantac Versus Omeprazole]] | ||
|- | |- | ||
| AT LAST | | [[AT LAST]] | ||
| [[Antiretroviral Trial Looking At Sex And Treatment]] | | [[Antiretroviral Trial Looking At Sex And Treatment]] | ||
|- | |- | ||
| ATAC | | [[ATAC]] | ||
| [[Arimidex (Anastrozole), Tamoxifen And Combination Therapy]] | | [[Arimidex (Anastrozole), Tamoxifen And Combination Therapy]] | ||
|- | |- | ||
| ATBAT | | [[ATBAT]] | ||
| [[Anticoagulant Therapy With Bivalirudin To Assist In Pci 1St Inning Trial (Pci In Hit/Hitts)]] | | [[Anticoagulant Therapy With Bivalirudin To Assist In Pci 1St Inning Trial (Pci In Hit/Hitts)]] | ||
|- | |- | ||
| ATBC | | [[ATBC]] | ||
| [[Alpha-Tocopherol, Beta-Carotene Lung Cancer Prevention Study]] | | [[Alpha-Tocopherol, Beta-Carotene Lung Cancer Prevention Study]] | ||
|- | |- | ||
| ATHENA | | [[ATHENA]] | ||
| [[Effect Of Dronedarone On Cardiovascular Outcomes In High-Risk Patients With Atrial Fibrillation Or Atrial Flutter]] | | [[Effect Of Dronedarone On Cardiovascular Outcomes In High-Risk Patients With Atrial Fibrillation Or Atrial Flutter]] | ||
|- | |- | ||
| ATHEROMA | | [[ATHEROMA]] | ||
| [[Atorvastatin Therapy: Effects Of Reduction Of Macrophage Activity]] | | [[Atorvastatin Therapy: Effects Of Reduction Of Macrophage Activity]] | ||
|- | |- | ||
| ATICH | | [[ATICH]] | ||
| [[Antifibrinolytic Therapy In Acute Intracerebral Hemorrhage]] | | [[Antifibrinolytic Therapy In Acute Intracerebral Hemorrhage]] | ||
|- | |- | ||
| ATLANTIC | | [[ATLANTIC]] | ||
| [[Angina Treatments - - Lasers And Normal Therapies In Comparison]] | | [[Angina Treatments - - Lasers And Normal Therapies In Comparison]] | ||
|- | |- | ||
| ATLANTIS | | [[ATLANTIS]] | ||
| [[Alteplase Thrombolysis For Acute Noninterventional Therapy In Ischemic Stroke]] | | [[Alteplase Thrombolysis For Acute Noninterventional Therapy In Ischemic Stroke]] | ||
|- | |- | ||
| ATLAS | | [[ATLAS]] | ||
| [[Assessment Of Treatment With Lisinopril And Survival]] | | [[Assessment Of Treatment With Lisinopril And Survival]] | ||
|- | |- | ||
| ATLAS | | [[ATLAS]] | ||
| [[Acolysis During Treatment Of Lesions Affecting Saphenous Vein Bypass Grafts Assessment Of Treatment With Lisinopril And Survival]] | | [[Acolysis During Treatment Of Lesions Affecting Saphenous Vein Bypass Grafts Assessment Of Treatment With Lisinopril And Survival]] | ||
|- | |- | ||
| ATLAS - SVG | | [[ATLAS - SVG]] | ||
| [[Acolysis During Treatment Of Lesions Affecting Saphenous Vein Bypass Grafts]] | | [[Acolysis During Treatment Of Lesions Affecting Saphenous Vein Bypass Grafts]] | ||
|- | |- | ||
| ATLAST | | [[ATLAST]] | ||
| [[Antiplatelet Therapy Alone Versus Lovenox Plus Antiplatelet Therapy In Patients At Increased Risk Of Stent Thrombosis]] | | [[Antiplatelet Therapy Alone Versus Lovenox Plus Antiplatelet Therapy In Patients At Increased Risk Of Stent Thrombosis]] | ||
|- | |- | ||
| ATLAS-TIMI 46 | | [[ATLAS-TIMI 46]] | ||
| [[Anti-Xa Therapy To Lower Cardiovascular Events In Addition To Aspirin With Or Without Thienopyridine In Subjects With Acute Coronary Syndromes–Thrombolysis In Myocardial Infarction 46]] | | [[Anti-Xa Therapy To Lower Cardiovascular Events In Addition To Aspirin With Or Without Thienopyridine In Subjects With Acute Coronary Syndromes–Thrombolysis In Myocardial Infarction 46]] | ||
|- | |- | ||
| AtoZ | | [[AtoZ]] | ||
| [[Aggrastat To Zocor Study]] | | [[Aggrastat To Zocor Study]] | ||
|- | |- | ||
| ATRAMI | | [[ATRAMI]] | ||
| [[Baroreflex Sensitivity And Heart-Rate Variability In Prediction Of Total Cardiac Mortality After Myocardial Infarction. Atrami (Autonomic Tone And Reflexes After Myocardial Infarction) Investigators.]] | | [[Baroreflex Sensitivity And Heart-Rate Variability In Prediction Of Total Cardiac Mortality After Myocardial Infarction. Atrami (Autonomic Tone And Reflexes After Myocardial Infarction) Investigators.]] | ||
|- | |- | ||
| ATRIA | | [[ATRIA]] | ||
| [[The Anticoagulation And Risk Factors In Atrial Fibrillation Study]] | | [[The Anticoagulation And Risk Factors In Atrial Fibrillation Study]] | ||
|- | |- | ||
| ATRIA | | [[ATRIA]] | ||
| [[Anticoagulation And Risk Factors In Atrial Fibrillation ]] | | [[Anticoagulation And Risk Factors In Atrial Fibrillation ]] | ||
|- | |- | ||
| Atrial Arrhythmia Conversion Trial | | [[Atrial Arrhythmia Conversion Trial]] | ||
| [[Vernakalant Hydrochloride For Rapid Conversion Of Atrial Fibrillation]] | | [[Vernakalant Hydrochloride For Rapid Conversion Of Atrial Fibrillation]] | ||
|- | |- | ||
| ATS | | [[ATS]] | ||
| [[Amblyopia Treatment Study]] | | [[Amblyopia Treatment Study]] | ||
|- | |- | ||
| ATTACH | | [[ATTACH]] | ||
| [[Anti-Tnf Therapy Against Congestive Heart Failure Trial]] | | [[Anti-Tnf Therapy Against Congestive Heart Failure Trial]] | ||
|- | |- | ||
| ATTEST | | [[ATTEST]] | ||
| [[Atrial Therapy Efficacy And Safety Trial]] | | [[Atrial Therapy Efficacy And Safety Trial]] | ||
|- | |- | ||
| ATTRACT | | [[ATTRACT]] | ||
| [[Anti-Tnf Trial In Rheumatoid Arthritis With Ca2 Treatment ]] | | [[Anti-Tnf Trial In Rheumatoid Arthritis With Ca2 Treatment ]] | ||
|- | |- | ||
| AURORA | | [[AURORA]] | ||
| [[A Study To Evaluate The Use Of Rosuvastatin In Subjects On Regular Hemodialysis: An Assessment Of Survival And Cardiovascular Events]] | | [[A Study To Evaluate The Use Of Rosuvastatin In Subjects On Regular Hemodialysis: An Assessment Of Survival And Cardiovascular Events]] | ||
|- | |- | ||
| AVASIS | | [[AVASIS]] | ||
| [[Aspirin Versus Anticoagulants In Symptomatic Intracranial Stenosis]] | | [[Aspirin Versus Anticoagulants In Symptomatic Intracranial Stenosis]] | ||
|- | |- | ||
| AVERT | | [[AVERT]] | ||
| [[Atorvastatin Versus Revascularization Treatments]] | | [[Atorvastatin Versus Revascularization Treatments]] | ||
|- | |- | ||
| AVERT | | [[AVERT]] | ||
| [[Artificial Valve Endocarditis Reduction Trial]] | | [[Artificial Valve Endocarditis Reduction Trial]] | ||
|- | |- | ||
| AVID | | [[AVID]] | ||
| [[Antiarrhythmics Versus Implantable Defibrillators]] | | [[Antiarrhythmics Versus Implantable Defibrillators]] | ||
|- | |- | ||
| AVID | | [[AVID]] | ||
| [[Angiography Versus Intravascular Ultrasound-Directed Stent Placement]] | | [[Angiography Versus Intravascular Ultrasound-Directed Stent Placement]] | ||
|- | |- | ||
| AVID Electrical Storm Substudy | | [[AVID Electrical Storm Substudy]] | ||
| [[Electrical Storm Presages Nonsudden Death. The Antiarrhythmics Vs. Implantable Defibrillators (Avid) Trial]] | | [[Electrical Storm Presages Nonsudden Death. The Antiarrhythmics Vs. Implantable Defibrillators (Avid) Trial]] | ||
|- | |- | ||
| AVOID | | [[AVOID]] | ||
| [[Aliskiren In The Evaluation Of Proteinuria In Diabetes]] | | [[Aliskiren In The Evaluation Of Proteinuria In Diabetes]] | ||
|- | |- | ||
| AWESOME | | [[AWESOME]] | ||
| [[Angina With Extremely Serious Operative Mortality Evaluation]] | | [[Angina With Extremely Serious Operative Mortality Evaluation]] | ||
|- | |- | ||
| AZACS | | [[AZACS]] | ||
| [[Azithromycin In Acute Coronary Syndrome]] | | [[Azithromycin In Acute Coronary Syndrome]] | ||
|- | |- | ||
| BAATAF | | [[BAATAF]] | ||
| [[Boston Area Anticoagulation Trial For Atrial Fibrillation]] | | [[Boston Area Anticoagulation Trial For Atrial Fibrillation]] | ||
|- | |- | ||
| BACH | | [[BACH]] | ||
| [[Bach]] | | [[Bach]] | ||
|- | |- | ||
| BARI | | [[BARI]] | ||
| [[Bypass Angioplasty Revascularization Investigation]] | | [[Bypass Angioplasty Revascularization Investigation]] | ||
|- | |- | ||
| BARI 2D | | [[BARI 2D]] | ||
| [[Bypass Angioplasty Revascularization Investigation In Type 2 Diabetics]] | | [[Bypass Angioplasty Revascularization Investigation In Type 2 Diabetics]] | ||
|- | |- | ||
| BARS | | [[BARS]] | ||
| [[Beaumont Alcohol Restenosis Study]] | | [[Beaumont Alcohol Restenosis Study]] | ||
|- | |- | ||
| BASC | | [[BASC]] | ||
| [[Blood Pressure In Acute Stroke Collaboration]] | | [[Blood Pressure In Acute Stroke Collaboration]] | ||
|- | |- | ||
| BASEL | | [[BASEL]] | ||
| [[Brain Natriuretic Peptide For Acute Shortness Of Breath Evaluation: A Randomized Comparison]] | | [[Brain Natriuretic Peptide For Acute Shortness Of Breath Evaluation: A Randomized Comparison]] | ||
|- | |- | ||
| BASIS | | [[BASIS]] | ||
| [[Basel Antiarrhythmic Study Of Infarct Survival]] | | [[Basel Antiarrhythmic Study Of Infarct Survival]] | ||
|- | |- | ||
| BASKET | | [[BASKET]] | ||
| [[Basel Stent Cost-Effectiveness Trial]] | | [[Basel Stent Cost-Effectiveness Trial]] | ||
|- | |- | ||
| BASKET LATE | | [[BASKET LATE]] | ||
| [[Late Clinical Events Related To Late Stent Thrombosis After Stopping Clopidogrel]] | | [[Late Clinical Events Related To Late Stent Thrombosis After Stopping Clopidogrel]] | ||
|- | |- | ||
| BAT | | [[BAT]] | ||
| [[Bivalirudin Angioplasty Study]] | | [[Bivalirudin Angioplasty Study]] | ||
|- | |- | ||
| BATMAN | | [[BATMAN]] | ||
| [[Biodivysio 'Bat'Imastat Sv Stent Versus Balloon Angioplasty For The Reduction Of Restenosis In Small Coronary Arteries ]] | | [[Biodivysio 'Bat'Imastat Sv Stent Versus Balloon Angioplasty For The Reduction Of Restenosis In Small Coronary Arteries ]] | ||
|- | |- | ||
| BBC ONE | | [[BBC ONE]] | ||
| [[British Bifurcation Coronary Study: Old, New, And Evolving Strategies]] | | [[British Bifurcation Coronary Study: Old, New, And Evolving Strategies]] | ||
|- | |- | ||
| BBS—Cognitive Study | | [[BBS—Cognitive Study]] | ||
| [[Best Bypass Surgery—Cognitive Study]] | | [[Best Bypass Surgery—Cognitive Study]] | ||
|- | |- | ||
| BCAPS | | [[BCAPS]] | ||
| [[Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study]] | | [[Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study]] | ||
|- | |- | ||
| BCPT | | [[BCPT]] | ||
| [[Breast Cancer Prevention Trial]] | | [[Breast Cancer Prevention Trial]] | ||
|- | |- | ||
| BEACH | | [[BEACH]] | ||
| [[Boston Scientific Epi: A Carotid Stenting Trial For High-Risk Surgical Patients]] | | [[Boston Scientific Epi: A Carotid Stenting Trial For High-Risk Surgical Patients]] | ||
|- | |- | ||
| BEAT | | [[BEAT]] | ||
| [[Bucindolol Evaluation In Acute Myocardial Infarction Trial ]] | | [[Bucindolol Evaluation In Acute Myocardial Infarction Trial ]] | ||
|- | |- | ||
| BEAUTIFUL | | [[BEAUTIFUL]] | ||
| [[Morbidity-Mortality Evaluation Of The If Inhibitor Ivabradine In Patients With Coronary Disease And Left-Ventricular Dysfunction]] | | [[Morbidity-Mortality Evaluation Of The If Inhibitor Ivabradine In Patients With Coronary Disease And Left-Ventricular Dysfunction]] | ||
|- | |- | ||
| BECAIT | | [[BECAIT]] | ||
| [[Bezafibrate Coronary Atherosclerosis Intervention Trial]] | | [[Bezafibrate Coronary Atherosclerosis Intervention Trial]] | ||
|- | |- | ||
| BECAIT | | [[BECAIT]] | ||
| [[Bezafibrate Coronary Atherosclerosis Intervention Trial]] | | [[Bezafibrate Coronary Atherosclerosis Intervention Trial]] | ||
|- | |- | ||
| BELLES | | [[BELLES]] | ||
| [[Beyond Endorsed Lipid Lowering With Ebt Scanning]] | | [[Beyond Endorsed Lipid Lowering With Ebt Scanning]] | ||
|- | |- | ||
| [[BENEDICT]] | |||
| [[ | |||
| [[Bergamo Nephrologic Diabetes Complications Trial]] | | [[Bergamo Nephrologic Diabetes Complications Trial]] | ||
|- | |- | ||
| BENEFiT | | [[BENEFiT]] | ||
| [[Bosentan Effects In Inoperable Forms Of Chronic Thromboembolic Pulmonary Hypertension]] | | [[Bosentan Effects In Inoperable Forms Of Chronic Thromboembolic Pulmonary Hypertension]] | ||
|- | |- | ||
| BENEFIT | | [[BENEFIT]] | ||
| [[Betaferon (Betaseron In U.S.) In Newly Emerging Ms For Initial Treatment Information]] | | [[Betaferon (Betaseron In U.S.) In Newly Emerging Ms For Initial Treatment Information]] | ||
|- | |- | ||
| [[BENESTENT I]] | |||
| [[ | |||
| [[Belgian-Netherlands Stent Study (I)]] | | [[Belgian-Netherlands Stent Study (I)]] | ||
|- | |- | ||
| BENESTENT II | | [[BENESTENT II]] | ||
| [[Belgian-Netherlands Stent Study II (Pilot)]] | | [[Belgian-Netherlands Stent Study II (Pilot)]] | ||
|- | |- | ||
| BERT | | [[BERT]] | ||
| [[Beta Energy Restenosis Trial - 1]] | | [[Beta Energy Restenosis Trial - 1]] | ||
|- | |- | ||
| [[BESMART]] | |||
| [[ | |||
| [[Bestent In Small Arteries Trial]] | | [[Bestent In Small Arteries Trial]] | ||
|- | |- | ||
| [[BESSAMI]] | |||
| [[ | |||
| [[Berlin Stent Study In Acute Myocardial Infarction]] | | [[Berlin Stent Study In Acute Myocardial Infarction]] | ||
|- | |- | ||
| BEST | | [[BEST]] | ||
| [[Beta Blocker Evaluation Of Survival Trial]] | | [[Beta Blocker Evaluation Of Survival Trial]] | ||
|- | |- | ||
| BEST | | [[BEST]] | ||
| [[Balloon Equivalent To Stent Trial]] | | [[Balloon Equivalent To Stent Trial]] | ||
|- | |- | ||
| [[BEST-ICD]] | |||
| [[ | |||
| [[Beta-Blocker Evaluation Of Survival Trial Plus Icd]] | | [[Beta-Blocker Evaluation Of Survival Trial Plus Icd]] | ||
|- | |- | ||
| BETA WRIST | | [[BETA WRIST]] | ||
| [[Washington Radiation For In-Stent Restenosis Trial]] | | [[Washington Radiation For In-Stent Restenosis Trial]] | ||
|- | |- | ||
| BETACATH | | [[BETACATH]] | ||
| [[Clinical And Angiographic Outcomes After Use Of Sr-90 Beta Radiation For The Treatment Of De Novo And Restenotic Coronary Lesions]] | | [[Clinical And Angiographic Outcomes After Use Of Sr-90 Beta Radiation For The Treatment Of De Novo And Restenotic Coronary Lesions]] | ||
|- | |- | ||
| BETTER | | [[BETTER]] | ||
| [[Beta Radiation Trial To Eliminate Restenosis]] | | [[Beta Radiation Trial To Eliminate Restenosis]] | ||
|- | |- | ||
| [[BHACAS]] | |||
| [[ | |||
| [[Early And Midterm Outcome After Off-Pump And On-Pump Surgery In Beating Heart Against Cardioplegic Arrest Studies (Bhacas 1 And 2): A Pooled Analysis Of Two Randomised Controlled Trials.]] | | [[Early And Midterm Outcome After Off-Pump And On-Pump Surgery In Beating Heart Against Cardioplegic Arrest Studies (Bhacas 1 And 2): A Pooled Analysis Of Two Randomised Controlled Trials.]] | ||
|- | |- | ||
| [[BHAT]] | |||
| [[ | |||
| [[Beta Blocker Heart Attack Trial]] | | [[Beta Blocker Heart Attack Trial]] | ||
|- | |- | ||
| BiCard | | [[BiCard]] | ||
| [[Biphasic Vs. Monophasic Shock Waveform For Conversion Of Atrial Fibrillation. The Results Of An International Randomized, Double-Blind Multicenter Trial]] | | [[Biphasic Vs. Monophasic Shock Waveform For Conversion Of Atrial Fibrillation. The Results Of An International Randomized, Double-Blind Multicenter Trial]] | ||
|- | |- | ||
| BICC | | [[BICC]] | ||
| [[Beta-Interferon In Chronic Viral Cardiomyopathy]] | | [[Beta-Interferon In Chronic Viral Cardiomyopathy]] | ||
|- | |- | ||
| BIP | | [[BIP]] | ||
| [[Bezafibrate Infarction Prevention Study]] | | [[Bezafibrate Infarction Prevention Study]] | ||
|- | |- | ||
| [[BIRD]] | |||
| [[ | |||
| [[ Bolus Versus Infusion In Rescupase (Saruplase) Development]] | | [[ Bolus Versus Infusion In Rescupase (Saruplase) Development]] | ||
|- | |- | ||
| BLIND-DATE | | [[BLIND-DATE]] | ||
| [[Blinded Withdrawal Of Deprenyl In The Datatop Extension Trial]] | | [[Blinded Withdrawal Of Deprenyl In The Datatop Extension Trial]] | ||
|- | |- | ||
| BLOSS | | [[BLOSS]] | ||
| [[Beta Blocker Length Of Stay Study]] | | [[Beta Blocker Length Of Stay Study]] | ||
|- | |- | ||
| BNP | | [[BNP]] | ||
| [[Breathing Not Properly]] | | [[Breathing Not Properly]] | ||
|- | |- | ||
| BOAT | | [[BOAT]] | ||
| [[Balloon Angioplasty Versus Optimal Atherectomy Trial]] | | [[Balloon Angioplasty Versus Optimal Atherectomy Trial]] | ||
|- | |- | ||
| Bogalusa | | [[Bogalusa]] | ||
| [[Bogalusa Heart Study]] | | [[Bogalusa Heart Study]] | ||
|- | |- | ||
| BOOST | | [[BOOST]] | ||
| [[Bone Marrow Transfer To Enhance St-Elevation Infarct Regeneration]] | | [[Bone Marrow Transfer To Enhance St-Elevation Infarct Regeneration]] | ||
|- | |- | ||
| BPAV | | [[BPAV]] | ||
| [[Balloon Prophylaxis Of Aneurysmal Vasospasm]] | | [[Balloon Prophylaxis Of Aneurysmal Vasospasm]] | ||
|- | |- | ||
| BRAINS | | [[BRAINS]] | ||
| [[Bayer Randomized Acute Ischemia Neuroprotectant Study]] | | [[Bayer Randomized Acute Ischemia Neuroprotectant Study]] | ||
|- | |- | ||
| BRAVE | | [[BRAVE]] | ||
| [[Bavarian Reperfusion Alternatives Evaluation]] | | [[Bavarian Reperfusion Alternatives Evaluation]] | ||
|- | |- | ||
| BRAVE-2 | | [[BRAVE-2]] | ||
| [[Beyond 12 Hours Reperfusion Alternative Evaluation Trial]] | | [[Beyond 12 Hours Reperfusion Alternative Evaluation Trial]] | ||
|- | |- | ||
| BRAVE-3 | | [[BRAVE-3]] | ||
| [[Value Of Abciximab In Patients With Ami Undergoing Pci After High Loading Dose Of Clopidogrel Pretreatment]] | | [[Value Of Abciximab In Patients With Ami Undergoing Pci After High Loading Dose Of Clopidogrel Pretreatment]] | ||
|- | |- | ||
| BRAVO | | [[BRAVO]] | ||
| [[Blockade Of The Glycoprotein IIb/IIia Receptor To Avoid Vascular Occlusion]] | | [[Blockade Of The Glycoprotein IIb/IIia Receptor To Avoid Vascular Occlusion]] | ||
|- | |- | ||
| BRAVO | | [[BRAVO]] | ||
| [[Beta Radiation For Treatment Of Arteriovenous Graft Outflow Sponsor:]] | | [[Beta Radiation For Treatment Of Arteriovenous Graft Outflow Sponsor:]] | ||
|- | |- | ||
| BREATHE-1 | | [[BREATHE-1]] | ||
| [[Bosentan (Tracleer): Randomized Trial Of Endothelin Receptor Antagonist Therapy For Pulmonary Hypertension]] | | [[Bosentan (Tracleer): Randomized Trial Of Endothelin Receptor Antagonist Therapy For Pulmonary Hypertension]] | ||
|- | |- | ||
| BRIDGE | | [[BRIDGE]] | ||
| [[Beta-Radiation Investigation With Direct Stenting And Galileo In Europe]] | | [[Beta-Radiation Investigation With Direct Stenting And Galileo In Europe]] | ||
|- | |- | ||
| BRIE | | [[BRIE]] | ||
| [[Beta Radiation In Europe]] | | [[Beta Radiation In Europe]] | ||
|- | |- | ||
| BRIEF-PCI | | [[BRIEF-PCI]] | ||
| [[Brief Infusion Of Eptifibatide Following Percutaneous Coronary Intervention]] | | [[Brief Infusion Of Eptifibatide Following Percutaneous Coronary Intervention]] | ||
|- | |- | ||
| BRILLIANT | | [[BRILLIANT]] | ||
| [[Batimastat (Bb-94) Antirestenosis Trial Utilizing The Biodivysio Local Drug Delivery Pc Stent ]] | | [[Batimastat (Bb-94) Antirestenosis Trial Utilizing The Biodivysio Local Drug Delivery Pc Stent ]] | ||
|- | |- | ||
| [[BRITE]] | |||
| [[ | |||
| [[Beta Radiation To Reduce In-Stent Restenosis ]] | | [[Beta Radiation To Reduce In-Stent Restenosis ]] | ||
|- | |- | ||
| BRITE II | | [[BRITE II]] | ||
| [[Beta Radiation To Reduce In-Stent Restenosis II]] | | [[Beta Radiation To Reduce In-Stent Restenosis II]] | ||
|- | |- | ||
| BRITE-SVG | | [[BRITE-SVG]] | ||
| [[Beta Radiation To Reduce In-Stent Restenosis In Saphenous Vein Grafts]] | | [[Beta Radiation To Reduce In-Stent Restenosis In Saphenous Vein Grafts]] | ||
|- | |- | ||
| [[CABERNET]] | |||
| [[ | |||
| [[A Prospective Registry Of Carotid Stenting With The Nexstent And Distal Protection With The Filterwire Ex In High Risk Patients]] | | [[A Prospective Registry Of Carotid Stenting With The Nexstent And Distal Protection With The Filterwire Ex In High Risk Patients]] | ||
|- | |- | ||
| CABERNET | | [[CABERNET]] | ||
| [[Carotid Artery Revascularization Using The Boston Scientific Epi Filterwire Ex And The Endotex Nexstent]] | | [[Carotid Artery Revascularization Using The Boston Scientific Epi Filterwire Ex And The Endotex Nexstent]] | ||
|- | |- | ||
| CABG PATCH | | [[CABG PATCH]] | ||
| [[The Coronary Artery Bypass Graft Patch Trial]] | | [[The Coronary Artery Bypass Graft Patch Trial]] | ||
|- | |- | ||
| CABG Patch Cardioplegia Substudy | | [[CABG Patch Cardioplegia Substudy]] | ||
| [[Does Cardioplegia Type Affect Outcome And Survival In Patients With Advanced Left Ventricular Dysfunction? Results From The Cabg Patch Tria]] | | [[Does Cardioplegia Type Affect Outcome And Survival In Patients With Advanced Left Ventricular Dysfunction? Results From The Cabg Patch Tria]] | ||
|- | |- | ||
| CABRI | | [[CABRI]] | ||
| [[Coronary Angioplasty Versus Bypass Revascularization Investigation]] | | [[Coronary Angioplasty Versus Bypass Revascularization Investigation]] | ||
|- | |- | ||
| CACAF | | [[CACAF]] | ||
| [[Catheter Ablation For The Cure Of Atrial Fibrillation Study]] | | [[Catheter Ablation For The Cure Of Atrial Fibrillation Study]] | ||
|- | |- | ||
| CACHET | | [[CACHET]] | ||
| [[Comparison Of Abciximab Complications With Hirulog (Angiomax As Of 1999) Ischemic Events Trial]] | | [[Comparison Of Abciximab Complications With Hirulog (Angiomax As Of 1999) Ischemic Events Trial]] | ||
|- | |- | ||
| CACTUS | | [[CACTUS]] | ||
| [[Coronary Bifurcations: Application Of The Crushing Technique Using Sirolimus-Eluting Stents]] | | [[Coronary Bifurcations: Application Of The Crushing Technique Using Sirolimus-Eluting Stents]] | ||
|- | |- | ||
| [[CADILLAC]] | |||
| [[ | |||
| [[Controlled Abciximab (Reopro) And Device Investigation To Lower Late Angioplasty Complications]] | | [[Controlled Abciximab (Reopro) And Device Investigation To Lower Late Angioplasty Complications]] | ||
|- | |- | ||
| CAESAR | | [[CAESAR]] | ||
| [[Canada, Australia, Europe, South Africa Aids Study ]] | | [[Canada, Australia, Europe, South Africa Aids Study ]] | ||
|- | |- | ||
| CAFA | | [[CAFA]] | ||
| [[Canadian Atrial Fibrillation Anticoagulation Study]] | | [[Canadian Atrial Fibrillation Anticoagulation Study]] | ||
|- | |- | ||
| CAFE | | [[CAFE]] | ||
| [[Conduit Artery Function Evaluation]] | | [[Conduit Artery Function Evaluation]] | ||
|- | |- | ||
| [[CALM]] | |||
| [[ | |||
| [[Candesartan And Lisinopril Microalbuminuria Study]] | | [[Candesartan And Lisinopril Microalbuminuria Study]] | ||
|- | |- | ||
| CALM-PD | | [[CALM-PD]] | ||
| [[Comparison Of The Agonist Pramipexole Vs. Levodopa On Motor Complications In Parkinson Disease]] | | [[Comparison Of The Agonist Pramipexole Vs. Levodopa On Motor Complications In Parkinson Disease]] | ||
|- | |- | ||
| CALYPSO | | [[CALYPSO]] | ||
| [[Cylexin As An Adjunct To Lytic Therapy To Prevent Superoxide Reflow Injury]] | | [[Cylexin As An Adjunct To Lytic Therapy To Prevent Superoxide Reflow Injury]] | ||
|- | |- | ||
| [[CAMELOT]] | |||
| [[ | |||
| [[Comparison Of Amlodipine Versus Enalapril (Lipitor) To Limit Occurrences Of Thrombosis]] | | [[Comparison Of Amlodipine Versus Enalapril (Lipitor) To Limit Occurrences Of Thrombosis]] | ||
|- | |- | ||
| CAMEO | | [[CAMEO]] | ||
| [[Cerebral Aneurysm Multicenter European]] | | [[Cerebral Aneurysm Multicenter European]] | ||
|- | |- | ||
| CAMIAT | | [[CAMIAT]] | ||
| [[Canadian Amiodarone Myocardial Infarction Arrhythmia Trial (Pilot)]] | | [[Canadian Amiodarone Myocardial Infarction Arrhythmia Trial (Pilot)]] | ||
|- | |- | ||
| [[CANDLE]] | |||
| [[ | |||
| [[Candesartan Versus Losartan Efficacy Comparison ]] | | [[Candesartan Versus Losartan Efficacy Comparison ]] | ||
|- | |- | ||
| Cangrelor during PCI | | [[Cangrelor during PCI]] | ||
| [[Cangrelor During Percutaneous Coronary Intervention]] | | [[Cangrelor During Percutaneous Coronary Intervention]] | ||
|- | |- | ||
| CANPAP | | [[CANPAP]] | ||
| [[Continuous Positive Airway Pressure For Heart Failure Patients With Central Sleep Apnea]] | | [[Continuous Positive Airway Pressure For Heart Failure Patients With Central Sleep Apnea]] | ||
|- | |- | ||
| [[CAPARES]] | |||
| [[ | |||
| [[Coronary Angioplasty Amlodipine Restenosis Study]] | | [[Coronary Angioplasty Amlodipine Restenosis Study]] | ||
|- | |- | ||
| CAPE II | | [[CAPE II]] | ||
| [[Medical Treatment Of Myocardial Ischemia In Coronary Artery Disease: Effect Of Drug Regime And Irregular Dosing In The Cape II Trial]] | | [[Medical Treatment Of Myocardial Ischemia In Coronary Artery Disease: Effect Of Drug Regime And Irregular Dosing In The Cape II Trial]] | ||
|- | |- | ||
| CAPITAL AMI | | [[CAPITAL AMI]] | ||
| [[Combined Angioplasty And Pharmacological Intervention Versus Thrombolytics Alone In Acute Myocardial Infarction]] | | [[Combined Angioplasty And Pharmacological Intervention Versus Thrombolytics Alone In Acute Myocardial Infarction]] | ||
|- | |- | ||
| CAPPP | | [[CAPPP]] | ||
| [[Captopril Prevention Project]] | | [[Captopril Prevention Project]] | ||
|- | |- | ||
| [[CAPRICORN]] | |||
| [[ | | [[Carvedilol Post Infarct Survival Control in Left Ventricular Dysfunction Study]] | ||
| [[Carvedilol Post | |||
|- | |- | ||
| [[CAPRIE]] | |||
| [[ | |||
| [[Clopidogrel Versus Aspirin In Patients At Risk Of Ischemic Events ]] | | [[Clopidogrel Versus Aspirin In Patients At Risk Of Ischemic Events ]] | ||
|- | |- | ||
| CAPS | | [[CAPS]] | ||
| [[The Cardiac Arrhythmic Pilot Study]] | | [[The Cardiac Arrhythmic Pilot Study]] | ||
|- | |- | ||
| CAPT | | [[CAPT]] | ||
| [[Complications Of Amd (Age-Related Macular Degeneration) Prevention Trial]] | | [[Complications Of Amd (Age-Related Macular Degeneration) Prevention Trial]] | ||
|- | |- | ||
| CAPTEN | | [[CAPTEN]] | ||
| [[Captopril After Thrombolysis Trial ]] | | [[Captopril After Thrombolysis Trial ]] | ||
|- | |- | ||
| CAPTIM | | [[CAPTIM]] | ||
| [[Comparison Of Angioplasty And Prehospital Thrombolysis In Acute Myocardial Infarction]] | | [[Comparison Of Angioplasty And Prehospital Thrombolysis In Acute Myocardial Infarction]] | ||
|- | |- | ||
| [[CAPTIN]] | |||
| [[ | | [[Captopril Plus Tissue Plasminogen Activator Following Acute Myocardial Infarction]] | ||
| [[Captopril Plus Tissue Plasminogen Activator Following Acute Myocardial Infarction]] | |||
|- | |- | ||
| CAPTIVATE | | [[CAPTIVATE]] | ||
| [[Carotid Atherosclerosis Progression Trial Investigating Vascular Acat Inhibition Treatment Effects]] | | [[Carotid Atherosclerosis Progression Trial Investigating Vascular Acat Inhibition Treatment Effects]] | ||
|- | |- | ||
| CAPTIVE | | [[CAPTIVE]] | ||
| [[A Prospective, Randomized, Controlled Trial Of Distal Protection With The Third Generation Mednova Emboshield Compared To The Guardwire Or Filterwire]] | | [[A Prospective, Randomized, Controlled Trial Of Distal Protection With The Third Generation Mednova Emboshield Compared To The Guardwire Or Filterwire]] | ||
|- | |- | ||
| CAPTURE | | [[CAPTURE]] | ||
| [[Chimeric 7E3 Antiplatelet Therapy In Unstable Angina Refractory To Standard Treatment]] | | [[Chimeric 7E3 Antiplatelet Therapy In Unstable Angina Refractory To Standard Treatment]] | ||
|- | |- | ||
| [[CAPTURE Registry]] | |||
| [[ | |||
| [[Carotid Acculink/Accunet Post-Approval Trial To Uncover Unanticipated Or Rare Events Registry]] | | [[Carotid Acculink/Accunet Post-Approval Trial To Uncover Unanticipated Or Rare Events Registry]] | ||
|- | |- | ||
| CARAT | | [[CARAT]] | ||
| [[Coronary Angioplasty And Rotational Atherectomy Trial]] | | [[Coronary Angioplasty And Rotational Atherectomy Trial]] | ||
|- | |- | ||
| CARDIA | | [[CARDIA]] | ||
| [[Coronary Artery Risk Development In Young Adults]] | | [[Coronary Artery Risk Development In Young Adults]] | ||
|- | |- | ||
| [[CARDia]] | |||
| [[ | |||
| [[Coronary Artery Revascularization In Diabetes Trial]] | | [[Coronary Artery Revascularization In Diabetes Trial]] | ||
|- | |- | ||
| CARDINAL | | [[CARDINAL]] | ||
| [[Complement And Reduction Of Infarct Size After Angioplasty Or Lytics]] | | [[Complement And Reduction Of Infarct Size After Angioplasty Or Lytics]] | ||
|- | |- | ||
| [[CARDS]] | |||
| [[ | |||
| [[Collaborative Atorvastatin (Lipitor) And Diabetes Study]] | | [[Collaborative Atorvastatin (Lipitor) And Diabetes Study]] | ||
|- | |- | ||
| CARE | | [[CARE]] | ||
| [[Cardiac Angiography In Renally Impaired Patients]] | | [[Cardiac Angiography In Renally Impaired Patients]] | ||
|- | |- | ||
| CARE | | [[CARE]] | ||
| [[Cholesterol And Recurrent Events]] | | [[Cholesterol And Recurrent Events]] | ||
|- | |- | ||
| CARE | | [[CARE]] | ||
| [[Calcium Antagonist In Reperfusion Cholesterol And Recurrent Events Carvedilol Atherectomy Restenosis ]] | | [[Calcium Antagonist In Reperfusion Cholesterol And Recurrent Events Carvedilol Atherectomy Restenosis ]] | ||
|- | |- | ||
| CARE-HD | | [[CARE-HD]] | ||
| [[Coenzyme Q10 And Remacemide: Evaluation In Huntington Disease]] | | [[Coenzyme Q10 And Remacemide: Evaluation In Huntington Disease]] | ||
|- | |- | ||
| CARE-HF | | [[CARE-HF]] | ||
| [[Cardiac Resynchronization - Heart Failure European Complement To U.S./Canada Miracle Study]] | | [[Cardiac Resynchronization - Heart Failure European Complement To U.S./Canada Miracle Study]] | ||
|- | |- | ||
| CARESS | | [[CARESS]] | ||
| [[Clopidogrel And Aspirin For Reduction Of Emboli In Symptomatic Carotid Stenosis]] | | [[Clopidogrel And Aspirin For Reduction Of Emboli In Symptomatic Carotid Stenosis]] | ||
|- | |- | ||
| CARESS-in-AMI: 30-Day and 1-Year Results | | [[CARESS-in-AMI: 30-Day and 1-Year Results]] | ||
| [[Combined Abciximab Reteplase Stent Study In Acute Myocardial Infarction]] | | [[Combined Abciximab Reteplase Stent Study In Acute Myocardial Infarction: 30-Day and 1-Year Results]] | ||
|- | |- | ||
| CARET | | [[CARET]] | ||
| [[The Beta Carotene And Retinol Efficacy Trial]] | | [[The Beta Carotene And Retinol Efficacy Trial]] | ||
|- | |- | ||
| CARIBE | | [[CARIBE]] | ||
| [[Carvedilol Insuficiencia Cardiaca (Heart Failure) Beta-Receptor]] | | [[Carvedilol Insuficiencia Cardiaca (Heart Failure) Beta-Receptor]] | ||
|- | |- | ||
| [[CARISA]] | |||
| [[ | |||
| [[Combination Assessment Of Ranolazine In Stable Angina ]] | | [[Combination Assessment Of Ranolazine In Stable Angina ]] | ||
|- | |- | ||
| CARMEN | | [[CARMEN]] | ||
| [[The Carvedilol And Ace-Inhibitor Remodeling Mild Heart Failure Evaluation Trial]] | | [[The Carvedilol And Ace-Inhibitor Remodeling Mild Heart Failure Evaluation Trial]] | ||
|- | |- | ||
| CARMEN | | [[CARMEN]] | ||
| [[Carvedilol Ace Inhibitors Remodelling Mild Heart Failure Evaluation]] | | [[Carvedilol Ace Inhibitors Remodelling Mild Heart Failure Evaluation]] | ||
|- | |- | ||
| CARP | | [[CARP]] | ||
| [[Coronary Artery Revascularization Prophylaxis]] | | [[Coronary Artery Revascularization Prophylaxis]] | ||
|- | |- | ||
| CARS | | [[CARS]] | ||
| [[Coumadin Aspirin Reinfarction Study]] | | [[Coumadin Aspirin Reinfarction Study]] | ||
|- | |- | ||
| [[CART]] | |||
| [[ | |||
| [[Canadian Antioxidant Restenosis Trial]] | | [[Canadian Antioxidant Restenosis Trial]] | ||
|- | |- | ||
| CARVEDILOL | | [[CARVEDILOL]] | ||
| [[The Effects Of Carvedilol On Morbidity And Mortality In Patients With Chronic Heart Failure]] | | [[The Effects Of Carvedilol On Morbidity And Mortality In Patients With Chronic Heart Failure]] | ||
|- | |- | ||
| CASCADE | | [[CASCADE]] | ||
| [[Cardiac Arrest In Seattle: Conventional Versus Amiodarone Drug Evaluation Study]] | | [[Cardiac Arrest In Seattle: Conventional Versus Amiodarone Drug Evaluation Study]] | ||
|- | |- | ||
| CASES | | [[CASES]] | ||
| [[Canadian Activase For Stroke Effectiveness Study]] | | [[Canadian Activase For Stroke Effectiveness Study]] | ||
|- | |- | ||
| [[CASH]] | |||
| [[ | |||
| [[Cardiac Arrest Study-Hamburg]] | | [[Cardiac Arrest Study-Hamburg]] | ||
|- | |- | ||
| CASIS | | [[CASIS]] | ||
| [[Canadian Amlodipine/Atenolol In Silent Ischemia Study]] | | [[Canadian Amlodipine/Atenolol In Silent Ischemia Study]] | ||
|- | |- | ||
| CASS | | [[CASS]] | ||
| [[Coronary Artery Surgery Study]] | | [[Coronary Artery Surgery Study]] | ||
|- | |- | ||
| CAST | | [[CAST]] | ||
| [[ | | [[Cardiac Arrhythmia Suppression Trial]] | ||
|- | |- | ||
| [[CASTEMI]] | |||
| [[ | |||
| [[Calderet In St Elevation Myocardial Infarction]] | | [[Calderet In St Elevation Myocardial Infarction]] | ||
|- | |- | ||
| CAST-II | | [[CAST-II]] | ||
| [[The Cardiac Arrhythmia Suppression Trial II]] | | [[The Cardiac Arrhythmia Suppression Trial II]] | ||
|- | |- | ||
| CASTLE | | [[CASTLE]] | ||
| [[Candesartan Amlodipine Study Of Tolerability And Efficacy]] | | [[Candesartan Amlodipine Study Of Tolerability And Efficacy]] | ||
|- | |- | ||
| CAT | | [[CAT]] | ||
| [[Cardiomyopathy Trial]] | | [[Cardiomyopathy Trial]] | ||
|- | |- | ||
| CAT | | [[CAT]] | ||
| [[Chinese Ace Inhibitor In Acute Myocardial Infarction Trial Cardiomyopathy Trial]] | | [[Chinese Ace Inhibitor In Acute Myocardial Infarction Trial Cardiomyopathy Trial]] | ||
|- | |- | ||
| CATAPULT | | [[CATAPULT]] | ||
| [[Cisplatin And Tirapazamine In Subjects With Advanced Previously Untreated Non–Small Cell Lung Tumors]] | | [[Cisplatin And Tirapazamine In Subjects With Advanced Previously Untreated Non–Small Cell Lung Tumors]] | ||
|- | |- | ||
| Cathedia Study | | [[Cathedia Study]] | ||
| [[Femoral Vs. Jugular Venous Catheterization And Risk Of Nosocomial Events In Adults Requiring Acute Renal Replacement Therapy]] | | [[Femoral Vs. Jugular Venous Catheterization And Risk Of Nosocomial Events In Adults Requiring Acute Renal Replacement Therapy]] | ||
|- | |- | ||
| CATIE | | [[CATIE]] | ||
| [[Clinical Antipsychotic Trials Of Intervention Effectiveness]] | | [[Clinical Antipsychotic Trials Of Intervention Effectiveness]] | ||
|- | |- | ||
| CATS | | [[CATS]] | ||
| [[Canadian American Ticlopidine Study]] | | [[Canadian American Ticlopidine Study]] | ||
|- | |- | ||
| CATS | | [[CATS]] | ||
| [[Captopril And Thrombolysis Study]] | | [[Captopril And Thrombolysis Study]] | ||
|- | |- | ||
| CAVATAS | | [[CAVATAS]] | ||
| [[Endovascular Versus Surgical Treatment In Patients With Carotid Stenosis In The Carotid And Vertebral Artery Transluminal Angioplasty Study (Cavatas)]] | | [[Endovascular Versus Surgical Treatment In Patients With Carotid Stenosis In The Carotid And Vertebral Artery Transluminal Angioplasty Study (Cavatas)]] | ||
|- | |- | ||
| [[CAVEAT I]] | |||
| [[ | |||
| [[Coronary Angioplasty Versus Excisional Atherectomy Trial I]] | | [[Coronary Angioplasty Versus Excisional Atherectomy Trial I]] | ||
|- | |- | ||
| CAVEAT II | | [[CAVEAT II]] | ||
| [[Coronary Angioplasty Versus Excisional Atherectomy Trial II]] | | [[Coronary Angioplasty Versus Excisional Atherectomy Trial II]] | ||
|- | |- | ||
| CBT-CD | | [[CBT-CD]] | ||
| [[Cognitive Behavior Therapy For The Chronic Depressions]] | | [[Cognitive Behavior Therapy For The Chronic Depressions]] | ||
|- | |- | ||
| CCAT | | [[CCAT]] | ||
| [[Canadian Coronary Atherectomy Trial]] | | [[Canadian Coronary Atherectomy Trial]] | ||
|- | |- | ||
| CCP | | [[CCP]] | ||
| [[The Cooperative Cardiovascular Project]] | | [[The Cooperative Cardiovascular Project]] | ||
|- | |- | ||
| CCS-1 | | [[CCS-1]] | ||
| [[Chinese Cardiac Study]] | | [[Chinese Cardiac Study]] | ||
|- | |- | ||
| CDP | | [[CDP]] | ||
| [[Coronary Drug Project]] | | [[Coronary Drug Project]] | ||
|- | |- | ||
| CEDARS | | [[CEDARS]] | ||
| [[Comprehensive Evaluation Of Defibrillators And Resuscitative Shock]] | | [[Comprehensive Evaluation Of Defibrillators And Resuscitative Shock]] | ||
|- | |- | ||
| CELL | | [[CELL]] | ||
| [[Cost Effectiveness Of Lipid Lowering Study]] | | [[Cost Effectiveness Of Lipid Lowering Study]] | ||
|- | |- | ||
| CEOS | | [[CEOS]] | ||
| [[Congenital Esotropia Observational Study]] | | [[Congenital Esotropia Observational Study]] | ||
|- | |- | ||
| CHAMP | | [[CHAMP]] | ||
| [[Combination Hemotherapy And Mortality Prevention (Champ) Study]] | | [[Combination Hemotherapy And Mortality Prevention (Champ) Study]] | ||
|- | |- | ||
| CHAMP | | [[CHAMP]] | ||
| [[Children's Hiv And Aids Model Program]] | | [[Children's Hiv And Aids Model Program]] | ||
|- | |- | ||
| CHAMPIONS | | [[CHAMPIONS]] | ||
| [[Controlled High-Risk Subjects Avonex Ms Prevention In Ongoing Neurologic Surveillance]] | | [[Controlled High-Risk Subjects Avonex Ms Prevention In Ongoing Neurologic Surveillance]] | ||
|- | |- | ||
| CHAMPS | | [[CHAMPS]] | ||
| [[Controlled High-Risk Subjects Avonex Ms Prevention Study]] | | [[Controlled High-Risk Subjects Avonex Ms Prevention Study]] | ||
|- | |- | ||
| CHAOS | | [[CHAOS]] | ||
| [[Cambridge Heart Antioxidant Study]] | | [[Cambridge Heart Antioxidant Study]] | ||
|- | |- | ||
| CHARISMA | | [[CHARISMA]] | ||
| [[Clopidogrel For High Atherothrombotic Risk, Ischemic Stabilization, Management, And Avoidance]] | | [[Clopidogrel For High Atherothrombotic Risk, Ischemic Stabilization, Management, And Avoidance]] | ||
|- | |- | ||
| CHARM | | [[CHARM]] | ||
| [[Candesartan Cilexitil (Atacand) In Heart Failure Assessment Of Reduction Mortality And Morbidity]] | | [[Candesartan Cilexitil (Atacand) In Heart Failure Assessment Of Reduction Mortality And Morbidity]] | ||
|- | |- | ||
| CHARM Added Trial | | [[CHARM Added Trial]] | ||
| [[Candesartan In Heart Failure—Added Trial]] | | [[Candesartan In Heart Failure—Added Trial]] | ||
|- | |- | ||
| CHARM Alternative Trial | | [[CHARM Alternative Trial]] | ||
| [[Candesartan In Heart Failure—Alternative Trial]] | | [[Candesartan In Heart Failure—Alternative Trial]] | ||
|- | |- | ||
| CHARM Overall Programme Results | | [[CHARM Overall Programme Results]] | ||
| [[Candesartan In Heart Failure—Assessment Of Reduction In Mortality And Morbidity]] | | [[Candesartan In Heart Failure—Assessment Of Reduction In Mortality And Morbidity]] | ||
|- | |- | ||
| CHARM Preserved Trial | | [[CHARM Preserved Trial]] | ||
| [[Candesartan In Heart Failure—Preserved Trial]] | | [[Candesartan In Heart Failure—Preserved Trial]] | ||
|- | |- | ||
| CHEESE | | [[CHEESE]] | ||
| [[Comparative Trial Of Hiv-Infected Patients Evaluating Efficacy And Safety Of Saquinavir-Enhanced Oral Formulation And Indinavir Given As Part Of A Triple Drug Therapy ]] | | [[Comparative Trial Of Hiv-Infected Patients Evaluating Efficacy And Safety Of Saquinavir-Enhanced Oral Formulation And Indinavir Given As Part Of A Triple Drug Therapy ]] | ||
|- | |- | ||
| [[CHF-STAT]] | |||
| [[ | |||
| [[Congestive Heart Failure Survival Trial Of Antiarrhythmic Therapy]] | | [[Congestive Heart Failure Survival Trial Of Antiarrhythmic Therapy]] | ||
|- | |- | ||
| CHICAGO | | [[CHICAGO]] | ||
| [[Carotid Intima-Media Thickness In Atherosclerosis Using Pioglitazone]] | | [[Carotid Intima-Media Thickness In Atherosclerosis Using Pioglitazone]] | ||
|- | |- | ||
| CHRISTMAS | | [[CHRISTMAS]] | ||
| [[Carvedilol Hibernating Reversible Ischaemia Trial]] | | [[Carvedilol Hibernating Reversible Ischaemia Trial]] | ||
|- | |- | ||
| [[CHS]] | |||
| [[ | |||
| [[Cardiovascular Health Study]] | | [[Cardiovascular Health Study]] | ||
----- | |||
---- [[CHS]] | |||
---- [[Charleston Heart Study]] | |||
----- | |||
---- [[CHS]] | |||
---- [[Community Health Study]] | |||
----- | |||
---- [[CHS]] | |||
---- [[Congenital Heart Surgeons Society Study]] | |||
----- | |||
---- [[CHS]] | |||
---- [[Coronary Heart Study]] | |||
|- | |- | ||
| [[CIAO]] | |||
| [[ | |||
| [[Coronary Interventions Antiplatelet-Based Only]] | | [[Coronary Interventions Antiplatelet-Based Only]] | ||
|- | |- | ||
| [[CIBIS]] | |||
| [[ | |||
| [[Cardiac Insufficiency Bisoprolol Study]] | | [[Cardiac Insufficiency Bisoprolol Study]] | ||
|- | |- | ||
| CIBIS II | | [[CIBIS II]] | ||
| [[The Cardiac Insufficiency Bisoprolol Study II]] | | [[The Cardiac Insufficiency Bisoprolol Study II]] | ||
|- | |- | ||
| CIBIS III | | [[CIBIS III]] | ||
| [[ | | [[The Cardiac Insufficiency Bisoprolol Study III]] | ||
|- | |- | ||
| CIDS | | [[CIDS]] | ||
| [[Canadian Implantable Defibrillator Study]] | | [[Canadian Implantable Defibrillator Study]] | ||
|- | |- | ||
| CIGTS | | [[CIGTS]] | ||
| [[Collaborative Initial Glaucoma Treatment Study]] | | [[Collaborative Initial Glaucoma Treatment Study]] | ||
|- | |- | ||
| CLARIDI | | [[CLARIDI]] | ||
| [[Cholesterol Lowering And Arrhythmias Recurrences After Internal Defibrillator Implantation]] | | [[Cholesterol Lowering And Arrhythmias Recurrences After Internal Defibrillator Implantation]] | ||
|- | |- | ||
| CLARITY-TIMI 28 | | [[CLARITY-TIMI 28]] | ||
| [[Clopidogrel As Adjunctive Reperfusion Therapy]] | | [[Clopidogrel As Adjunctive Reperfusion Therapy]] | ||
|- | |- | ||
| CLAS I AND II | | [[CLAS I AND II]] | ||
| [[Cholesterol Lowering Atherosclerosis Study (I And II)]] | | [[Cholesterol Lowering Atherosclerosis Study (I And II)]] | ||
|- | |- | ||
| CLASS | | [[CLASS]] | ||
| [[Celecoxib (Celebrex) Long-Term Arthritis Safety Study]] | | [[Celecoxib (Celebrex) Long-Term Arthritis Safety Study]] | ||
|- | |- | ||
| [[CLASSICS]] | |||
| [[ | |||
| [[Clopidogrel (Plavix) Aspirin Stent International Cooperative Study]] | | [[Clopidogrel (Plavix) Aspirin Stent International Cooperative Study]] | ||
|- | |- | ||
| CLASS-IHT | | [[CLASS-IHT]] | ||
| [[Clomethiazole Acute Stroke Study In Ischemic, Hemorrhagic, And Tpa Treated Stroke]] | | [[Clomethiazole Acute Stroke Study In Ischemic, Hemorrhagic, And Tpa Treated Stroke]] | ||
|- | |- | ||
| CLEAR PLATELETS | | [[CLEAR PLATELETS]] | ||
| [[Clopidogrel Loading With Eptifibatide To Arrest The Reactivity Of Platelets Study]] | | [[Clopidogrel Loading With Eptifibatide To Arrest The Reactivity Of Platelets Study]] | ||
|- | |- | ||
| CLEAR PLATELETS-2 | | [[CLEAR PLATELETS-2]] | ||
| [[Clopidogrel With Eptifibatide To Arrest The Reactivity Of Platelets]] | | [[Clopidogrel With Eptifibatide To Arrest The Reactivity Of Platelets-2]] | ||
|- | |- | ||
| CLEERE | | [[CLEERE]] | ||
| [[Collaborative Longitudinal Evaluation Of Ethnicity And Refractive Error]] | | [[Collaborative Longitudinal Evaluation Of Ethnicity And Refractive Error]] | ||
|- | |- | ||
| COACH | | [[COACH]] | ||
| [[Coordinating Study Evaluating Outcomes Of Advising And Counseling In Heart Failure]] | | [[Coordinating Study Evaluating Outcomes Of Advising And Counseling In Heart Failure]] | ||
|- | |- | ||
| [[COAST]] | |||
| [[ | |||
| [[Heparin-Coated Stents In Small Coronary Arteries]] | | [[Heparin-Coated Stents In Small Coronary Arteries]] | ||
|- | |- | ||
| COBALT | | [[COBALT]] | ||
| [[Continuous Infusion Versus Double-Bolus Administration Of Alteplase]] | | [[Continuous Infusion Versus Double-Bolus Administration Of Alteplase]] | ||
|- | |- | ||
| COCAD | | [[COCAD]] | ||
| [[Cognitive Outcomes In Coronary Artery Disease]] | | [[Cognitive Outcomes In Coronary Artery Disease]] | ||
|- | |- | ||
| COLA | | [[COLA]] | ||
| [[Carvedilol Open Label Assessment]] | | [[Carvedilol Open Label Assessment]] | ||
|- | |- | ||
| COLUMBUS | | [[COLUMBUS]] | ||
| [[Low Molecular Weight Heparin In The Treatment Of Patients With Venous Thromboembolism]] | | [[Low Molecular Weight Heparin In The Treatment Of Patients With Venous Thromboembolism]] | ||
|- | |- | ||
| COMBINE | | [[COMBINE]] | ||
| [[Combining Medications And Behavorial Interventions ]] | | [[Combining Medications And Behavorial Interventions ]] | ||
|- | |- | ||
| [[COMET]] | |||
| [[ | |||
| [[Carvedilol Or Metoprolol European Trial]] | | [[Carvedilol Or Metoprolol European Trial]] | ||
|- | |- | ||
| COMMA | | [[COMMA]] | ||
| [[Compliment Inhibition In Myocardial Infarction Treated With Percutaneous Transluminal Coronary Angioplasty (Evaluation Of Iv Dosing Regimens Of H5G1.1-Scfv) ]] | | [[Compliment Inhibition In Myocardial Infarction Treated With Percutaneous Transluminal Coronary Angioplasty (Evaluation Of Iv Dosing Regimens Of H5G1.1-Scfv) ]] | ||
|- | |- | ||
| COMMIT/CCS-2 – Clopidogrel | | [[COMMIT/CCS-2 – Clopidogrel]] | ||
| [[Randomized, Placebo-Controlled Trial Of Adding Clopidogrel To Aspirin In 46,000 Acute Myocardial Infarction Patients]] | | [[Randomized, Placebo-Controlled Trial Of Adding Clopidogrel To Aspirin In 46,000 Acute Myocardial Infarction Patients]] | ||
|- | |- | ||
| COMMIT/CCS-2 – Metoprolol | | [[COMMIT/CCS-2 – Metoprolol]] | ||
| [[Randomized, Placebo-Controlled Trial Of Early Metoprolol In 46,000 Acute Myocardial Infarction Patients]] | | [[Randomized, Placebo-Controlled Trial Of Early Metoprolol In 46,000 Acute Myocardial Infarction Patients]] | ||
|- | |- | ||
| [[COMPANION]] | |||
| [[ | |||
| [[Comparison Of Medical Therapy, Pacing And Defibrillation In Chronic Heart Failure]] | | [[Comparison Of Medical Therapy, Pacing And Defibrillation In Chronic Heart Failure]] | ||
|- | |- | ||
| Comparison of GR-II Stent and Palmaz-Schatz Stent for Elective Treatment of Coronary Stenosis | | [[Comparison of GR-II Stent and Palmaz-Schatz Stent for Elective Treatment of Coronary Stenosis]] | ||
| [[Randomized Clinical Trial Investigators. Randomized Comparison Of Gr-II Stent And Palmaz-Schatz Stent For Elective Treatment Of Coronary Stenosis]] | | [[Randomized Clinical Trial Investigators. Randomized Comparison Of Gr-II Stent And Palmaz-Schatz Stent For Elective Treatment Of Coronary Stenosis]] | ||
|- | |- | ||
| Comparison of Ibuprofen and Indomethacin for Closure of Patent Ductus Arteriosus | | [[Comparison of Ibuprofen and Indomethacin for Closure of Patent Ductus Arteriosus]] | ||
| [[A Comparison Of Ibuprofen And Indomethacin For Closure Of Patent Ductus Arteriosus]] | | [[A Comparison Of Ibuprofen And Indomethacin For Closure Of Patent Ductus Arteriosus]] | ||
|- | |- | ||
| COMPASS | | [[COMPASS]] | ||
| [[Comparison Trial Of Saruplase And Streptokinase]] | | [[Comparison Trial Of Saruplase And Streptokinase]] | ||
|- | |- | ||
| COMPASS-HF | | [[COMPASS-HF]] | ||
| [[Chronicle Offers Management To Patients With Advanced Signs And Symptoms Of Heart Failure]] | | [[Chronicle Offers Management To Patients With Advanced Signs And Symptoms Of Heart Failure]] | ||
|- | |- | ||
| COMPLY | | [[COMPLY]] | ||
| [[Compliment Inhibition In Myocardial Infarction Treated With Thrombolytics | | [[Compliment Inhibition In Myocardial Infarction Treated With Thrombolytics (Evaluation Of Iv Dosing Regimens Of H5G1.1-Scfv) Sponsors]] | ||
|- | |- | ||
| COMS | | [[COMS]] | ||
| [[Collaborative Ocular Melanoma Study]] | | [[Collaborative Ocular Melanoma Study]] | ||
|- | |- | ||
| CONSENSUS | | [[CONSENSUS]] | ||
| [[The Effects Of Enalapril On Mortality In Severe Congestive Heart Failure]] | | [[The Effects Of Enalapril On Mortality In Severe Congestive Heart Failure]] | ||
|- | |- | ||
| CONSENSUS II | | [[CONSENSUS II]] | ||
| [[The Effects Of The Early Administration Of Enalapril On Mortality In Patients With Acute Myocardial Infarction: Results Of The Cooperative New Scandin]] | | [[The Effects Of The Early Administration Of Enalapril On Mortality In Patients With Acute Myocardial Infarction: Results Of The Cooperative New Scandin-2]] | ||
|- | |- | ||
| CONVERTIBLE | | [[CONVERTIBLE]] | ||
| [[Conventional Stenting Versus Direct Stenting In (Un)Stable Angina Pectoris]] | | [[Conventional Stenting Versus Direct Stenting In (Un)Stable Angina Pectoris]] | ||
|- | |- | ||
| CONVINCE | | [[CONVINCE]] | ||
| [[Controlled Onset Verapamil Investigation Of Cardiovascular Endpoints Trial]] | | [[Controlled Onset Verapamil Investigation Of Cardiovascular Endpoints Trial]] | ||
|- | |- | ||
| [[COOL]] | |||
| [[ | |||
| [[Cardiovascular Thrombolytic To Open Occluded Lines]] | | [[Cardiovascular Thrombolytic To Open Occluded Lines]] | ||
|- | |- | ||
| COOL AID | | [[COOL AID]] | ||
| [[Cooling For Acute Ischemic Brain Damage]] | | [[Cooling For Acute Ischemic Brain Damage]] | ||
|- | |- | ||
| COOL MI | | [[COOL MI]] | ||
| [[Cooling As An Adjunctive Therapy To Percutaneous Intervention In Patients With Acute Myocardial Infarction]] | | [[Cooling As An Adjunctive Therapy To Percutaneous Intervention In Patients With Acute Myocardial Infarction]] | ||
|- | |- | ||
| COOLRCN | | [[COOLRCN]] | ||
| [[Cooling To Prevent Radiocontrast Nephropathy]] | | [[Cooling To Prevent Radiocontrast Nephropathy]] | ||
|- | |- | ||
| COPERNICUS | | [[COPERNICUS]] | ||
| [[Effect Of Carvedilol On Survival In Severe Chronic Heart Failure]] | | [[Effect Of Carvedilol On Survival In Severe Chronic Heart Failure]] | ||
|- | |- | ||
| [[COPPA]] | |||
| [[ | |||
| [[Clinical Outcomes From The Prevention Of Postoperative Arrhythmia]] | | [[Clinical Outcomes From The Prevention Of Postoperative Arrhythmia]] | ||
|- | |- | ||
| CORE | | [[CORE]] | ||
| [[International Variation In Invasive Procedures And Outcomes In Acute Myocardial Infarction]] | | [[International Variation In Invasive Procedures And Outcomes In Acute Myocardial Infarction]] | ||
|- | |- | ||
| CORE | | [[CORE]] | ||
| [[Continuing Outcomes Relevant To Evista]] | | [[Continuing Outcomes Relevant To Evista]] | ||
|- | |- | ||
| CORONA | | [[CORONA]] | ||
| [[Controlled Rosuvastatin Multinational Trial In Heart Failure]] | | [[Controlled Rosuvastatin Multinational Trial In Heart Failure]] | ||
|- | |- | ||
| CORSICA | | [[CORSICA]] | ||
| [[Chronic Occlusion Revascularization With Stent Implantation Versus Coronary Angioplasty]] | | [[Chronic Occlusion Revascularization With Stent Implantation Versus Coronary Angioplasty]] | ||
|- | |- | ||
| COSS | | [[COSS]] | ||
| [[Carotid Occlusion Surgery Study]] | | [[Carotid Occlusion Surgery Study]] | ||
|- | |- | ||
| COURAGE | | [[COURAGE]] | ||
| [[Clinical Outcomes Utilizing Revascularization And Aggressive Drug Evaluation ]] | | [[Clinical Outcomes Utilizing Revascularization And Aggressive Drug Evaluation ]] | ||
|- | |- | ||
| [[COURT]] | |||
| [[ | |||
| [[Contrast Utilization In High Risk Patients Undergoing Ptca]] | | [[Contrast Utilization In High Risk Patients Undergoing Ptca]] | ||
|- | |- | ||
| [[C-PORT]] | |||
| [[ | |||
| [[Atlantic Cardiovascular Patient Outcomes Research Team Trial]] | | [[Atlantic Cardiovascular Patient Outcomes Research Team Trial]] | ||
|- | |- | ||
| CPVA for Chronic Atrial Fibrillation | | [[CPVA for Chronic Atrial Fibrillation]] | ||
| [[Circumferential Pulmonary Vein Ablation For Chronic Atrial Fibrillation]] | | [[Circumferential Pulmonary Vein Ablation For Chronic Atrial Fibrillation]] | ||
|- | |- | ||
| CQI in CABG | | [[CQI in CABG]] | ||
| [[Continuous Quality Improvement In Coranary Artery Bypass Graft]] | | [[Continuous Quality Improvement In Coranary Artery Bypass Graft]] | ||
|- | |- | ||
| CRASH | | [[CRASH]] | ||
| [[Corticosteroid Randomization After Significant Head Injury]] | | [[Corticosteroid Randomization After Significant Head Injury]] | ||
|- | |- | ||
| CREATE | | [[CREATE]] | ||
| [[Canadian Cardiac Randomized Evaluation Of Antidepressant And Psychotherapy Efficacy]] | | [[Canadian Cardiac Randomized Evaluation Of Antidepressant And Psychotherapy Efficacy]] | ||
|- | |- | ||
| CREATE ELCA - Reviparin | | [[CREATE ELCA - Reviparin]] | ||
| [[Low Molecular Weight Heparin (Reviparin) In Preventing Mortality, Reinfarction, And Strokes In Over 15,500 Patients With St Elevation Acute Myocardial Infarction]] | | [[Low Molecular Weight Heparin (Reviparin) In Preventing Mortality, Reinfarction, And Strokes In Over 15,500 Patients With St Elevation Acute Myocardial Infarction]] | ||
|- | |- | ||
| CREATE-ECLA - GIK | | [[CREATE-ECLA - GIK]] | ||
| [[Impact Of Glucose-Insulin-Potassium On Mortality And Morbidity In Over 20,000 Patients With Acute Myocardial Infarction: The Create-Ecla International Trial]] | | [[Impact Of Glucose-Insulin-Potassium On Mortality And Morbidity In Over 20,000 Patients With Acute Myocardial Infarction: The Create-Ecla International Trial]] | ||
|- | |- | ||
| CREDO | | [[CREDO]] | ||
| [[Clopidogrel For Reduction Of Events During Observation]] | | [[Clopidogrel For Reduction Of Events During Observation]] | ||
|- | |- | ||
| [[CREST]] | |||
| [[ | |||
| [[Cilostazol For Restenosis]] | | [[Cilostazol For Restenosis]] | ||
|- | |- | ||
| CREST | | [[CREST]] | ||
| [[Carotid Revascularization Endarterectomy Vs Stenting Trial]] | | [[Carotid Revascularization Endarterectomy Vs Stenting Trial]] | ||
|- | |- | ||
| CRIS | | [[CRIS]] | ||
| [[A Controlled Trial Of Verapamil In Patients After Acute Myocardial Infarction: Results Of The Calcium, Antagonist Reinfarction Italian Study]] | | [[A Controlled Trial Of Verapamil In Patients After Acute Myocardial Infarction: Results Of The Calcium, Antagonist Reinfarction Italian Study]] | ||
|- | |- | ||
| [[CRUISE]] | |||
| [[ | |||
| [[Can Routine Ultrasound Influence Stent Expansion]] | | [[Can Routine Ultrasound Influence Stent Expansion]] | ||
|- | |- | ||
| C-SIRIUS | | [[C-SIRIUS]] | ||
| [[Canadian Sirolimus-Eluting Stent In Coronary Lesions]] | | [[Canadian Sirolimus-Eluting Stent In Coronary Lesions]] | ||
|- | |- | ||
| CSSS | | [[CSSS]] | ||
| [[China Salt Substitute Study]] | | [[China Salt Substitute Study]] | ||
|- | |- | ||
| CTAF | | [[CTAF]] | ||
| [[Canadian Trial Of Atrial Fibrillation]] | | [[Canadian Trial Of Atrial Fibrillation]] | ||
|- | |- | ||
| CTOPP | | [[CTOPP]] | ||
| [[Canadian Trial Of Physiologic Pacing]] | | [[Canadian Trial Of Physiologic Pacing]] | ||
|- | |- | ||
| CUBA | | [[CUBA]] | ||
| [[Cutting Balloon Versus Conventional Angioplasty Study]] | | [[Cutting Balloon Versus Conventional Angioplasty Study]] | ||
|- | |- | ||
| CURE | | [[CURE]] | ||
| [[The Clopidogrel In Unstable Angina To Prevent Recurrent Events Trial Investigators: Effects Of Clopidogrel In Addition To Aspirin In Patients With Acute Coronary Syndromes Without St-Segment Elevation]] | | [[The Clopidogrel In Unstable Angina To Prevent Recurrent Events Trial Investigators: Effects Of Clopidogrel In Addition To Aspirin In Patients With Acute Coronary Syndromes Without St-Segment Elevation]] | ||
|- | |- | ||
| CURE | | [[CURE]] | ||
| [[Clopidogrel In Unstable Angina To Prevent Recurrent Ischemic Events]] | | [[Clopidogrel In Unstable Angina To Prevent Recurrent Ischemic Events]] | ||
|- | |- | ||
| DAIS | | [[DAIS]] | ||
| [[Diabetes Atherosclerosis Intervention Study]] | | [[Diabetes Atherosclerosis Intervention Study]] | ||
|- | |- | ||
| [[DAISY]] | |||
| [[ | |||
| [[Diabetes Autoimmunity Study In The Young]] | | [[Diabetes Autoimmunity Study In The Young]] | ||
|- | |- | ||
| DANAMI | | [[DANAMI]] | ||
| [[Danish Myocardial Infarction Trial]] | | [[Danish Myocardial Infarction Trial]] | ||
|- | |- | ||
| DANAMI-2 | | [[DANAMI-2]] | ||
| [[Danish Trial In Acute Myocardial Infarction-2]] | | [[Danish Trial In Acute Myocardial Infarction-2]] | ||
|- | |- | ||
| DANTE | | [[DANTE]] | ||
| [[Diabetes Abciximab Stent Evaluation]] | | [[Diabetes Abciximab Stent Evaluation]] | ||
|- | |- | ||
| DAPPAF | | [[DAPPAF]] | ||
| [[Dual Site Atrial Pacing To Prevent Atrial Fibrillation]] | | [[Dual Site Atrial Pacing To Prevent Atrial Fibrillation]] | ||
|- | |- | ||
| DART | | [[DART]] | ||
| [[Dilation Versus Ablation Revascularization Trial]] | | [[Dilation Versus Ablation Revascularization Trial]] | ||
|- | |- | ||
| DASH | | [[DASH]] | ||
| [[Dietary Approaches To Stop Hypertension]] | | [[Dietary Approaches To Stop Hypertension]] | ||
|- | |- | ||
| DATATOP | | [[DATATOP]] | ||
| [[Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism]] | | [[Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism]] | ||
|- | |- | ||
| [[DAVID]] | |||
| [[ | |||
| [[Dual-Chamber And Vvi Implantable Defibrillator]] | | [[Dual-Chamber And Vvi Implantable Defibrillator]] | ||
|- | |- | ||
| DAVID – (Picotamide vs. Aspirin) | | [[DAVID – (Picotamide vs. Aspirin)]] | ||
| [[Drug Evaluation In Atherosclerotic Vascular Disease In Diabetics]] | | [[Drug Evaluation In Atherosclerotic Vascular Disease In Diabetics]] | ||
|- | |- | ||
| DAVID II | | [[DAVID II]] | ||
| [[Dual Chamber And Vvi Implantable Defibrillator II]] | | [[Dual Chamber And Vvi Implantable Defibrillator II]] | ||
|- | |- | ||
| DAVIT II | | [[DAVIT II]] | ||
| [[Danish Study Group On Verapamil In Mi]] | | [[Danish Study Group On Verapamil In Mi]] | ||
|- | |- | ||
| DCCT | | [[DCCT]] | ||
| [[Diabetes Control And Complications Trial]] | | [[Diabetes Control And Complications Trial]] | ||
|- | |- | ||
| DEAR-MI | | [[DEAR-MI]] | ||
| [[Dethrombosis To Enhance Acute Reperfusion In Myocardial Infarction]] | | [[Dethrombosis To Enhance Acute Reperfusion In Myocardial Infarction]] | ||
|- | |- | ||
| DEBATE | | [[DEBATE]] | ||
| [[Doppler Endpoints Balloon Angioplasty Trial Europe]] | | [[Doppler Endpoints Balloon Angioplasty Trial Europe]] | ||
|- | |- | ||
| [[DEBATE II]] | |||
| [[ | | [[Doppler Endpoints Balloon Angioplasty Trial Europe-2]] | ||
| [[Doppler Endpoints Balloon Angioplasty Trial Europe]] | |||
|- | |- | ||
| DEBUT | | [[DEBUT]] | ||
| [[Defibrillator Versus Beta-Blockers For Unexplained Death In Thailand]] | | [[Defibrillator Versus Beta-Blockers For Unexplained Death In Thailand]] | ||
|- | |- | ||
| DECLARE-DIABETES | | [[DECLARE-DIABETES]] | ||
| [[Drug-Eluting Stenting Followed By Cilostazol Treatment Reduces Late Restenosis In Patients With Diabetes Mellitus]] | | [[Drug-Eluting Stenting Followed By Cilostazol Treatment Reduces Late Restenosis In Patients With Diabetes Mellitus]] | ||
|- | |- | ||
| DECOPI | | [[DECOPI]] | ||
| [[Randomized Trial Of Occluded Artery Angioplasty After Acute Myocardial Infarction]] | | [[Randomized Trial Of Occluded Artery Angioplasty After Acute Myocardial Infarction]] | ||
|- | |- | ||
| DECOPI | | [[DECOPI]] | ||
| [[La Desobstruction Coronaire En Post-Infarctus ]] | | [[La Desobstruction Coronaire En Post-Infarctus ]] | ||
|- | |- | ||
| DECREASE III | | [[DECREASE III]] | ||
| [[Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echo III]] | | [[Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echo III]] | ||
|- | |- | ||
| DECREASE-V | | [[DECREASE-V]] | ||
| [[Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echo-V]] | | [[Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echo-V]] | ||
|- | |- | ||
| DEDICATION: Distal Protection Study | | [[DEDICATION: Distal Protection Study]] | ||
| [[Drug Elution And Distal Protection In St-Elevation Myocardial Infarction]] | | [[Drug Elution And Distal Protection In St-Elevation Myocardial Infarction]] | ||
|- | |- | ||
| DEDICATION: Stent Study | | [[DEDICATION: Stent Study]] | ||
| [[Drug Elution And Distal Protection In Acute Myocardial Infarction]] | | [[Drug Elution And Distal Protection In Acute Myocardial Infarction]] | ||
|- | |- | ||
| DEFER | | [[DEFER]] | ||
| [[Deferral Versus Performance Of Ptca In Patients Without Documented Ischemia]] | | [[Deferral Versus Performance Of Ptca In Patients Without Documented Ischemia]] | ||
|- | |- | ||
| [[DEFINITE]] | |||
| [[ | |||
| [[Defibrillators In Nonischemic Cardiomyopathy Treatment Evaluation]] | | [[Defibrillators In Nonischemic Cardiomyopathy Treatment Evaluation]] | ||
|- | |- | ||
| DEFUSE | | [[DEFUSE]] | ||
| [[Diffusion-Weighted Imaging Evaluation For Understanding Stroke Evaluation ]] | | [[Diffusion-Weighted Imaging Evaluation For Understanding Stroke Evaluation ]] | ||
|- | |- | ||
| DELTA MI | | [[DELTA MI]] | ||
| [[Direct Inhibition Of Δ-Protein Kinase C Enzyme To Limit Total Infarct Size In Acute Mi]] | | [[Direct Inhibition Of Δ-Protein Kinase C Enzyme To Limit Total Infarct Size In Acute Mi]] | ||
|- | |- | ||
| DES-DIABETES | | [[DES-DIABETES]] | ||
| [[A Randomized Comparison Of Sirolimus- Versus Paclitaxel-Eluting Stent Implantation In Patients With Diabetes Mellitus]] | | [[A Randomized Comparison Of Sirolimus- Versus Paclitaxel-Eluting Stent Implantation In Patients With Diabetes Mellitus]] | ||
|- | |- | ||
| DESTINI-CFR | | [[DESTINI-CFR]] | ||
| [[Doppler Endpoints Stenting International Investigation - Coronary Flow Reserve ]] | | [[Doppler Endpoints Stenting International Investigation - Coronary Flow Reserve ]] | ||
|- | |- | ||
| DETAIL | | [[DETAIL]] | ||
| [[Diabetics Exposed To Telmisartan And Enalapril]] | | [[Diabetics Exposed To Telmisartan And Enalapril]] | ||
|- | |- | ||
| [[DIABETES]] | |||
| [[ | |||
| [[A Prospective, Randomized, Controlled Trial Of The Polymer-Based, Sirolimus-Eluting Stent Versus A Bare Metal Stent In Patients With Diabetes Mellitus]] | | [[A Prospective, Randomized, Controlled Trial Of The Polymer-Based, Sirolimus-Eluting Stent Versus A Bare Metal Stent In Patients With Diabetes Mellitus]] | ||
|- | |- | ||
| DIACOR | | [[DIACOR]] | ||
| [[Diabetes And Combined Lipid Therapy Regimen]] | | [[Diabetes And Combined Lipid Therapy Regimen]] | ||
|- | |- | ||
| DIAD | | [[DIAD]] | ||
| [[Detection Of Ischemia In Asymptomatic Diabetics]] | | [[Detection Of Ischemia In Asymptomatic Diabetics]] | ||
|- | |- | ||
| DIADS | | [[DIADS]] | ||
| [[Depression In Alzheimer Disease Study]] | | [[Depression In Alzheimer Disease Study]] | ||
|- | |- | ||
| DIAGNOSIS | | [[DIAGNOSIS]] | ||
| [[Diffusion-Weighted Imaging Assessment Of The Genuine Need For Other Studies In Ischemic Stroke]] | | [[Diffusion-Weighted Imaging Assessment Of The Genuine Need For Other Studies In Ischemic Stroke]] | ||
|- | |- | ||
| DIAL | | [[DIAL]] | ||
| [[Randomized Trial Of Telephone Intervention In Chronic Heart Failure]] | | [[Randomized Trial Of Telephone Intervention In Chronic Heart Failure]] | ||
|- | |- | ||
| DIAMOND | | [[DIAMOND]] | ||
| [[Danish Investigations Of Arrhythmia And Mortality On Dofetilide]] | | [[Danish Investigations Of Arrhythmia And Mortality On Dofetilide]] | ||
|- | |- | ||
| DIAMOND | | [[DIAMOND]] | ||
| [[Distensibility Improvement With Alt-711 Remodeling In Diastolic Heart Failure Sponsor]] | | [[Distensibility Improvement With Alt-711 Remodeling In Diastolic Heart Failure Sponsor]] | ||
|- | |- | ||
| DIAMOND CHF | | [[DIAMOND CHF]] | ||
| [[Danish Investigators Of Arrhythmia And Mortality On Dofetilde Congestive Heart Failure ]] | | [[Danish Investigators Of Arrhythmia And Mortality On Dofetilde Congestive Heart Failure ]] | ||
|- | |- | ||
| DIDI | | [[DIDI]] | ||
| [[Diltiazem In Dilated Cardiomyopathy]] | | [[Diltiazem In Dilated Cardiomyopathy]] | ||
|- | |- | ||
| DIG | | [[DIG]] | ||
| [[Digoxin Investigation Group]] | | [[Digoxin Investigation Group]] | ||
|- | |- | ||
| DIG Enalapril | | [[DIG Enalapril]] | ||
| [[Enalapril Versus Digoxin In Patients With Congestive Heart Failure: A Multicenter Study (Canadian Enalapril Versus Digoxin Study Group)]] | | [[Enalapril Versus Digoxin In Patients With Congestive Heart Failure: A Multicenter Study (Canadian Enalapril Versus Digoxin Study Group)]] | ||
|- | |- | ||
| [[DIGAMI]] | |||
| [[ | |||
| [[Diabetes Mellitus Insulin-Glucose Infusion In Acute Myocardial Infarction]] | | [[Diabetes Mellitus Insulin-Glucose Infusion In Acute Myocardial Infarction]] | ||
|- | |- | ||
| DIMT | | [[DIMT]] | ||
| [[Double-Blind Placebo-Controlled Study Of Ibopamine And Digoxin In Patients With Mild To Moderate Heart Failure: Results Of The Dutch Ibopamine Multic]] | | [[Double-Blind Placebo-Controlled Study Of Ibopamine And Digoxin In Patients With Mild To Moderate Heart Failure: Results Of The Dutch Ibopamine Multic]] | ||
|- | |- | ||
| [[DINAMIT]] | |||
| [[ | |||
| [[Defibrillation In Acute Myocardial Infarction Trial]] | | [[Defibrillation In Acute Myocardial Infarction Trial]] | ||
|- | |- | ||
| DIPOM | | [[DIPOM]] | ||
| [[Diabetic Postoperative Mortality And Morbidity Trial]] | | [[Diabetic Postoperative Mortality And Morbidity Trial]] | ||
|- | |- | ||
| DIRECT | | [[DIRECT]] | ||
| [[Direct Stenting Using The Sirolimus-Eluting Stent]] | | [[Direct Stenting Using The Sirolimus-Eluting Stent]] | ||
|- | |- | ||
| DIRECT | | [[DIRECT]] | ||
| [[Direct Myocardial Revascularization In Regeneration Of Endocardial Channels Trial]] | | [[Direct Myocardial Revascularization In Regeneration Of Endocardial Channels Trial]] | ||
|- | |- | ||
| DIRECT | | [[DIRECT]] | ||
| [[Diabetic Retinopathy Candesartan Trial Candesartan Cilexetil (Atacand)]] | | [[Diabetic Retinopathy Candesartan Trial Candesartan Cilexetil (Atacand)]] | ||
|- | |- | ||
| DIRECTOR | | [[DIRECTOR]] | ||
| [[Direct Stenting Study With Orbus R Stent]] | | [[Direct Stenting Study With Orbus R Stent]] | ||
|- | |- | ||
| DISC | | [[DISC]] | ||
| [[Disability In Strategies For Care]] | | [[Disability In Strategies For Care]] | ||
|- | |- | ||
| DISCO | | [[DISCO]] | ||
| [[Direct Coronary Stenting Versus Stenting With Balloon Predilation: Immediate And Follow-Up Results]] | | [[Direct Coronary Stenting Versus Stenting With Balloon Predilation: Immediate And Follow-Up Results]] | ||
|- | |- | ||
| DISTINCT | | [[DISTINCT]] | ||
| [[Biodivysio Stent In Controlled Trial]] | | [[Biodivysio Stent In Controlled Trial]] | ||
|- | |- | ||
| DMIST | | [[DMIST]] | ||
| [[Digital Mammographic Imaging Screening Trial]] | | [[Digital Mammographic Imaging Screening Trial]] | ||
|- | |- | ||
| DPP | | [[DPP]] | ||
| [[Diabetes Prevention Program Trial]] | | [[Diabetes Prevention Program Trial]] | ||
|- | |- | ||
| DPT-1 | | [[DPT-1]] | ||
| [[Diabetes Prevention Trial - Type 1 ]] | | [[Diabetes Prevention Trial - Type 1 ]] | ||
|- | |- | ||
| DREAM | | [[DREAM]] | ||
| [[Diabetes Reduction Approaches With Ramipril And Rosiglitazone Medications]] | | [[Diabetes Reduction Approaches With Ramipril And Rosiglitazone Medications]] | ||
|- | |- | ||
| DREAM - Ramipril | | [[DREAM - Ramipril]] | ||
| [[Diabetes Reduction Assessment With Ramipril And Rosiglitazone Medication]] | | [[Diabetes Reduction Assessment With Ramipril And Rosiglitazone Medication]] | ||
|- | |- | ||
| DREAM - Rosiglitazone | | [[DREAM - Rosiglitazone]] | ||
| [[Diabetes Reduction Assessment With Ramipril And Rosiglitazone Medication]] | | [[Diabetes Reduction Assessment With Ramipril And Rosiglitazone Medication]] | ||
|- | |- | ||
| DUCCS-1 | | [[DUCCS-1]] | ||
| [[Duke University Clinical Cardiology Study - 1]] | | [[Duke University Clinical Cardiology Study - 1]] | ||
|- | |- | ||
| DUCCS-2 | | [[DUCCS-2]] | ||
| [[Duke University Clinical Cardiology Study - 2]] | | [[Duke University Clinical Cardiology Study - 2]] | ||
|- | |- | ||
| DYSBOT | | [[DYSBOT]] | ||
| [[Dysport And Botox Study ]] | | [[Dysport And Botox Study ]] | ||
|- | |- | ||
| EAFT | | [[EAFT]] | ||
| [[European Atrial Fibrillation Trial]] | | [[European Atrial Fibrillation Trial]] | ||
|- | |- | ||
| EAGAR | | [[EAGAR]] | ||
| [[Estrogen And Graft Atherosclerosis Research Trial]] | | [[Estrogen And Graft Atherosclerosis Research Trial]] | ||
|- | |- | ||
| EARLY | | [[EARLY]] | ||
| [[Eptifibatide For Acute Coronary Syndromes—Rapid Versus Late Administration For Therapeutic Yield]] | | [[Eptifibatide For Acute Coronary Syndromes—Rapid Versus Late Administration For Therapeutic Yield]] | ||
|- | |- | ||
| EARLY | | [[EARLY]] | ||
| [[Endothelin Antagonist Trial In Mildly Symptomatic Pulmonary Arterial Hypertension Patient]] | | [[Endothelin Antagonist Trial In Mildly Symptomatic Pulmonary Arterial Hypertension Patient]] | ||
|- | |- | ||
| EARLY ACS | | [[EARLY ACS]] | ||
| [[Early Glycoprotein IIb/IIia Inhibition In Non–St-Segment Elevation Acute Coronary Syndromes]] | | [[Early Glycoprotein IIb/IIia Inhibition In Non–St-Segment Elevation Acute Coronary Syndromes]] | ||
|- | |- | ||
| EARS | | [[EARS]] | ||
| [[European Atherosclerosis Research Study]] | | [[European Atherosclerosis Research Study]] | ||
|- | |- | ||
| EARTH | | [[EARTH]] | ||
| [[Endothelin Receptor Antagonist Trial In Heart Failure]] | | [[Endothelin Receptor Antagonist Trial In Heart Failure]] | ||
|- | |- | ||
| EASE | | [[EASE]] | ||
| [[Ezetimibe Add-On To Statin Therapy For Effectiveness Trial]] | | [[Ezetimibe Add-On To Statin Therapy For Effectiveness Trial]] | ||
|- | |- | ||
| EAST | | [[EAST]] | ||
| [[Emory Angioplasty Vs Surgery Trial]] | | [[Emory Angioplasty Vs Surgery Trial]] | ||
|- | |- | ||
| EASTER | | [[EASTER]] | ||
| [[Estrogen And Stents To Eliminate Restenosis]] | | [[Estrogen And Stents To Eliminate Restenosis]] | ||
|- | |- | ||
| EASY | | [[EASY]] | ||
| [[Early Discharge After Transradial Stenting Of Coronary Arteries]] | | [[Early Discharge After Transradial Stenting Of Coronary Arteries]] | ||
|- | |- | ||
| EASYAS | | [[EASYAS]] | ||
| [[Eastbourne Syncope Assessment Study]] | | [[Eastbourne Syncope Assessment Study]] | ||
|- | |- | ||
| ECASS III | | [[ECASS III]] | ||
| [[European Cooperative Acute Stroke Study III]] | | [[European Cooperative Acute Stroke Study III]] | ||
|- | |- | ||
| ECCE | | [[ECCE]] | ||
| [[Effects Of Captopril On Cardiopulmonary Exercise Parameters (Ecce)]] | | [[Effects Of Captopril On Cardiopulmonary Exercise Parameters (Ecce)]] | ||
|- | |- | ||
| ECCO 2000 | | [[ECCO 2000]] | ||
| [[Effects Of Citicoline (Ceraxon) On Clinical Outcome - 2000 Mg ]] | | [[Effects Of Citicoline (Ceraxon) On Clinical Outcome - 2000 Mg ]] | ||
|- | |- | ||
| ECHO in PPH | | [[ECHO in PPH]] | ||
| [[Echocardiographic Predictors Of Adverse Outcomes In Primary Pulmonary Hypertension.]] | | [[Echocardiographic Predictors Of Adverse Outcomes In Primary Pulmonary Hypertension.]] | ||
|- | |- | ||
| ECLA GIK | | [[ECLA GIK]] | ||
| [[Estudios Cardiologicos Latinoamerica Glucose-Insulin-Potassium Pilot Trial]] | | [[Estudios Cardiologicos Latinoamerica Glucose-Insulin-Potassium Pilot Trial]] | ||
|- | |- | ||
| ECLIPSE | | [[ECLIPSE]] | ||
| [[Ensure's Vascular Closure Device Speeds Hemostasis Trial]] | | [[Ensure's Vascular Closure Device Speeds Hemostasis Trial]] | ||
|- | |- | ||
| ECRIS | | [[ECRIS]] | ||
| [[Endocoronary-Rhenium-Irradiation-Study]] | | [[Endocoronary-Rhenium-Irradiation-Study]] | ||
|- | |- | ||
| ECSG-1 | | [[ECSG-1]] | ||
| [[European Cooperative Study Group For Recombinant Tissue-Type Plasminogen Activator]] | | [[European Cooperative Study Group For Recombinant Tissue-Type Plasminogen Activator]] | ||
|- | |- | ||
| ECSG-6 | | [[ECSG-6]] | ||
| [[European Cooperative Study Group For Recombinant Tissue-Type Plasminogen Activator II]] | | [[European Cooperative Study Group For Recombinant Tissue-Type Plasminogen Activator II]] | ||
|- | |- | ||
| ECSS | | [[ECSS]] | ||
| [[European Coronary Surgery Study Group]] | | [[European Coronary Surgery Study Group]] | ||
|- | |- | ||
| ECST | | [[ECST]] | ||
| [[European Carotid Surgery Trial]] | | [[European Carotid Surgery Trial]] | ||
|- | |- | ||
| EDGECAP | | [[EDGECAP]] | ||
| [[Evaluation Of Daptomycin (Cidecin) In Gram-Positive Entities In The Treatment Of Community-Acquired Pneumonia]] | | [[Evaluation Of Daptomycin (Cidecin) In Gram-Positive Entities In The Treatment Of Community-Acquired Pneumonia]] | ||
|- | |- | ||
| EDGESST | | [[EDGESST]] | ||
| [[Evaluation Of Daptomycin (Cidecin) In Gram-Positive Entities In The Treatment Of Complicated Skin And Soft Tissue Infections]] | | [[Evaluation Of Daptomycin (Cidecin) In Gram-Positive Entities In The Treatment Of Complicated Skin And Soft Tissue Infections]] | ||
|- | |- | ||
| EDGE | | [[EDGE]] | ||
| [[Evaluation Of Daptomycin (Cidecin) In Gram-Positive Entities]] | | [[Evaluation Of Daptomycin (Cidecin) In Gram-Positive Entities]] | ||
|- | |- | ||
| EDGEUTI | | [[EDGEUTI]] | ||
| [[Evaluation Of Daptomycin (Cidecin) In Gram-Positive Entities In The Treatment Of Complicated Urinary Tract Infection]] | | [[Evaluation Of Daptomycin (Cidecin) In Gram-Positive Entities In The Treatment Of Complicated Urinary Tract Infection]] | ||
|- | |- | ||
| ED-IMPACT | | [[ED-IMPACT]] | ||
| [[Emergency Department Impedance Cardiography-Aided Assessment Changes Therapy Sponsor: Cardiodynamics International]] | | [[Emergency Department Impedance Cardiography-Aided Assessment Changes Therapy Sponsor: Cardiodynamics International]] | ||
|- | |- | ||
| EFICAT | | [[EFICAT]] | ||
| [[Ejection Fraction In Cardiac Transplant Patients]] | | [[Ejection Fraction In Cardiac Transplant Patients]] | ||
|- | |- | ||
| EGASIS | | [[EGASIS]] | ||
| [[Early Gaba-Ergic Activation Sin Troke]] | | [[Early Gaba-Ergic Activation Sin Troke]] | ||
|- | |- | ||
| ELATE | | [[ELATE]] | ||
| [[ Extended Low-Intensity Anticoagulation For Thrombo-Embolism Investigators]] | | [[Extended Low-Intensity Anticoagulation For Thrombo-Embolism Investigators]] | ||
|- | |- | ||
| ELECT | | [[ELECT]] | ||
| [[Evaluating Enoxaparin (Lovenox) Clotting Times]] | | [[Evaluating Enoxaparin (Lovenox) Clotting Times]] | ||
|- | |- | ||
| ELITE | | [[ELITE]] | ||
| [[Evaluation Of Losartan In The Elderly]] | | [[Evaluation Of Losartan In The Elderly]] | ||
|- | |- | ||
| [[ELITE-II]] | |||
| [[ | |||
| [[Losartan Heart Failure Survival Study]] | | [[Losartan Heart Failure Survival Study]] | ||
|- | |- | ||
| ELLDOPA | | [[ELLDOPA]] | ||
| [[Earlier Versus Later Levodopa In Parkinson Disease]] | | [[Earlier Versus Later Levodopa In Parkinson Disease]] | ||
|- | |- | ||
| ELUTES | | [[ELUTES]] | ||
| [[European Evaluation Of Paclitaxel Eluting Stent]] | | [[European Evaluation Of Paclitaxel Eluting Stent]] | ||
|- | |- | ||
| ELVD-CHF | | [[ELVD-CHF]] | ||
| [[Exercise In Left Ventricular Dysfunction And Chronic Heart Failure Trial]] | | [[Exercise In Left Ventricular Dysfunction And Chronic Heart Failure Trial]] | ||
|- | |- | ||
| EMERALD | | [[EMERALD]] | ||
| [[Enhanced Myocardial Efficacy And Removal By Aspiration Of Liberated Debris]] | | [[Enhanced Myocardial Efficacy And Removal By Aspiration Of Liberated Debris]] | ||
|- | |- | ||
| EMERALD | | [[EMERALD]] | ||
| [[European And Australian Multicenter Evaluative Research On Atrial Fibrillation—Dofetilide]] | | [[European And Australian Multicenter Evaluative Research On Atrial Fibrillation—Dofetilide]] | ||
|- | |- | ||
| EMERAS | | [[EMERAS]] | ||
| [[Estudio Multicentrico Estreptoquinasa Republicas De America Del Sur]] | | [[Estudio Multicentrico Estreptoquinasa Republicas De America Del Sur]] | ||
|- | |- | ||
| EMIAT | | [[EMIAT]] | ||
| [[European Myocardial Infarction Amiodarone Trial]] | | [[European Myocardial Infarction Amiodarone Trial]] | ||
|- | |- | ||
| EMIP | | [[EMIP]] | ||
| [[Prehospital Thrombolytic Therapy In Patients With Suspected Acute Myocardial Infarction]] | | [[Prehospital Thrombolytic Therapy In Patients With Suspected Acute Myocardial Infarction]] | ||
|- | |- | ||
| EMIP-FR | | [[EMIP-FR]] | ||
| [[European Myocardial Infarction Project—Free Radicals]] | | [[European Myocardial Infarction Project—Free Radicals]] | ||
|- | |- | ||
| EMIT | | [[EMIT]] | ||
| [[European Mivazerol Trial]] | | [[European Mivazerol Trial]] | ||
|- | |- | ||
| EMPIRIC | | [[EMPIRIC]] | ||
| [[Comparison Of Empiric To Physician-Tailored Programming Of Implantable Cardioverter Defibrillators Trial]] | | [[Comparison Of Empiric To Physician-Tailored Programming Of Implantable Cardioverter Defibrillators Trial]] | ||
|- | |- | ||
| ENABLE | | [[ENABLE]] | ||
| [[Effects Of The Endothelin Receptor Antagonist Bosentan On The Morbidity And Mortality In Patients With Chronic Heart Failure]] | | [[Effects Of The Endothelin Receptor Antagonist Bosentan On The Morbidity And Mortality In Patients With Chronic Heart Failure]] | ||
|- | |- | ||
| [[ENCOR]] | |||
| [[ | |||
| [[Enrasentan Cooperative Randomized Evaluation]] | | [[Enrasentan Cooperative Randomized Evaluation]] | ||
|- | |- | ||
| [[ENCORE I]] | |||
| [[ | |||
| [[Evaluation Of Nifedipine And Cerivastatin On Recovery Of Coronary Endothelial Function]] | | [[Evaluation Of Nifedipine And Cerivastatin On Recovery Of Coronary Endothelial Function]] | ||
|- | |- | ||
| ENCORE II | | [[ENCORE II]] | ||
| [[Long-Term Effect Of Nifedipine On Vasomotion And Vessel Morphology In Patients With Coronary Artery Disease: An Intravascular Ultrasound-Assisted Evaluation]] | | [[Long-Term Effect Of Nifedipine On Vasomotion And Vessel Morphology In Patients With Coronary Artery Disease: An Intravascular Ultrasound-Assisted Evaluation]] | ||
|- | |- | ||
| ENDEAVOR II | | [[ENDEAVOR II]] | ||
| [[Randomized Comparison Of The Endeavor Abt-578 Drug Eluting Stent With A Bare Metal Stent For Coronary Revascularization]] | | [[Randomized Comparison Of The Endeavor Abt-578 Drug Eluting Stent With A Bare Metal Stent For Coronary Revascularization]] | ||
|- | |- | ||
| ENDEAVOR III | | [[ENDEAVOR III]] | ||
| [[Randomized Comparison Of Zotarolimus-Eluting And Sirolimus-Eluting Stents In Patients With Coronary Artery Disease]] | | [[Randomized Comparison Of Zotarolimus-Eluting And Sirolimus-Eluting Stents In Patients With Coronary Artery Disease-3]] | ||
|- | |- | ||
| ENDEAVOR IV | | [[ENDEAVOR IV]] | ||
| [[Randomized Comparison Of Zotarolimus-Eluting And Paclitaxel-Eluting Stents In Patients With Coronary Artery Disease]] | | [[Randomized Comparison Of Zotarolimus-Eluting And Paclitaxel-Eluting Stents In Patients With Coronary Artery Disease-4]] | ||
|- | |- | ||
| ENDEAVOR-1 | | [[ENDEAVOR-1]] | ||
| [[Multicenter Evaluation Of Abt-578 Elution From A Phosphorylcholine-Coated Stent]] | | [[Multicenter Evaluation Of Abt-578 Elution From A Phosphorylcholine-Coated Stent]] | ||
|- | |- | ||
| ENHANCE | | [[ENHANCE]] | ||
| [[Simvastatin With Or Without Ezetimibe In Familial Hypercholesterolemia]] | | [[Simvastatin With Or Without Ezetimibe In Familial Hypercholesterolemia]] | ||
|- | |- | ||
| ENRICHD | | [[ENRICHD]] | ||
| [[Enhancing Recovery In Coronary Heart Disease]] | | [[Enhancing Recovery In Coronary Heart Disease]] | ||
|- | |- | ||
| [[ENTIRE]] | |||
| [[ | |||
| [[Enoxaparin And Tnk-Tpa With Or Without Gp IIb/IIia Inhibitor As Reperfusion Strategy In St Elevation Mi (TIMI-23) ]] | | [[Enoxaparin And Tnk-Tpa With Or Without Gp IIb/IIia Inhibitor As Reperfusion Strategy In St Elevation Mi (TIMI-23) ]] | ||
|- | |- | ||
| EPAMSA | | [[EPAMSA]] | ||
| [[Estudio Piloto Argentino De Muerte Subita Y Amioda Rone (Argentine Pilot Study Of Sudden Death And Amiodarone)]] | | [[Estudio Piloto Argentino De Muerte Subita Y Amioda Rone (Argentine Pilot Study Of Sudden Death And Amiodarone)]] | ||
|- | |- | ||
| EPAT | | [[EPAT]] | ||
| [[Estrogen In The Prevention Of Atherosclerosis Trial]] | | [[Estrogen In The Prevention Of Atherosclerosis Trial]] | ||
|- | |- | ||
| EPHESUS | | [[EPHESUS]] | ||
| [[Eplerenone Post-Ami Heart Failure Efficacy And Survival Study]] | | [[Eplerenone Post-Ami Heart Failure Efficacy And Survival Study]] | ||
|- | |- | ||
| [[EPIC]] | |||
| [[ | |||
| [[Evaluation Of C7E3 For The Prevention Of Ischemic Complications]] | | [[Evaluation Of C7E3 For The Prevention Of Ischemic Complications]] | ||
|- | |- | ||
| [[EPILOG]] | |||
| [[ | |||
| [[Evaluation Of Ptca To Improve Long-Term Outcome By C7E3 Gp IIb/IIia Receptor (Abciximab) Blockade]] | | [[Evaluation Of Ptca To Improve Long-Term Outcome By C7E3 Gp IIb/IIia Receptor (Abciximab) Blockade]] | ||
|- | |- | ||
| [[EPISTENT]] | |||
| [[ | |||
| [[Evaluation Of Platelet IIb/IIia Inhibitor For Stenting Trial]] | | [[Evaluation Of Platelet IIb/IIia Inhibitor For Stenting Trial]] | ||
|- | |- | ||
| EPOS | | [[EPOS]] | ||
| [[Elective Pci In Outpatient Study]] | | [[Elective Pci In Outpatient Study]] | ||
|- | |- | ||
| ERA | | [[ERA]] | ||
| [[Enoxaparin Restenosis (Era) Trial.]] | | [[Enoxaparin Restenosis (Era) Trial.]] | ||
|- | |- | ||
| ERA | | [[ERA]] | ||
| [[Early Rheumatoid Arthritis (Ra) Enoxaparin Restenosis After Angioplasty StudyEstrogen Replacement And Atherosclerosis Study]] | | [[Early Rheumatoid Arthritis (Ra) Enoxaparin Restenosis After Angioplasty StudyEstrogen Replacement And Atherosclerosis Study]] | ||
|- | |- | ||
| ERA (HRT) | | [[ERA (HRT)]] | ||
| [[Effect Of Estrogen Replacement On The Progression Of Coronary Artery Atherosclerosis]] | | [[Effect Of Estrogen Replacement On The Progression Of Coronary Artery Atherosclerosis]] | ||
|- | |- | ||
| ERACI | | [[ERACI]] | ||
| [[Estudio Randomizado Argentino De Angioplastia Vs. Cirugía (Argentine Randomized Trial Of Percutaneous Transluminal Coronary Angioplasty Versus Coronary Artery Bypass Surgery In Multivessel Disease)]] | | [[Estudio Randomizado Argentino De Angioplastia Vs. Cirugía (Argentine Randomized Trial Of Percutaneous Transluminal Coronary Angioplasty Versus Coronary Artery Bypass Surgery In Multivessel Disease)]] | ||
|- | |- | ||
| ERACI II | | [[ERACI II]] | ||
| [[Argentine Randomized Study: Coronary Angioplasty With Stenting Vs. Coronary Artery Bypass Surgery In Patients With Multiple-Vessel Disease (Eraci II): 30-Day And One Year Follow-Up Results]] | | [[Argentine Randomized Study: Coronary Angioplasty With Stenting Vs. Coronary Artery Bypass Surgery In Patients With Multiple-Vessel Disease (Eraci II): 30-Day And One Year Follow-Up Results]] | ||
|- | |- | ||
| ERASE | | [[ERASE]] | ||
| [[Emergency Room Assessment Of Sestamibi For Evaluation Of Chest Pain]] | | [[Emergency Room Assessment Of Sestamibi For Evaluation Of Chest Pain]] | ||
|- | |- | ||
| ERASE | | [[ERASE]] | ||
| [[Effects Of Rhdl On Atherosclerosis–Safety And Efficacy]] | | [[Effects Of Rhdl On Atherosclerosis–Safety And Efficacy]] | ||
|- | |- | ||
| ERASER | | [[ERASER]] | ||
| [[Evaluation Of Reopro And Stenting To Eliminate Restenosis]] | | [[Evaluation Of Reopro And Stenting To Eliminate Restenosis]] | ||
|- | |- | ||
| ERBAC | | [[ERBAC]] | ||
| [[Excimer Laser, Rotational Atherectomy, Balloon Angioplasty Complications Study]] | | [[Excimer Laser, Rotational Atherectomy, Balloon Angioplasty Complications Study]] | ||
|- | |- | ||
| ERGO | | [[ERGO]] | ||
| [[Etomoxir For The Recovery Of Glucose Oxidation]] | | [[Etomoxir For The Recovery Of Glucose Oxidation]] | ||
|- | |- | ||
| ERICA | | [[ERICA]] | ||
| [[Efficacy Of Ranolazine In Chronic Angina]] | | [[Efficacy Of Ranolazine In Chronic Angina]] | ||
|- | |- | ||
| ERNA | | [[ERNA]] | ||
| [[Early Return To Normal Activities At Two Weeks After Acute Myocardial Infarction: Preliminary Results Of A Randomized Study]] | | [[Early Return To Normal Activities At Two Weeks After Acute Myocardial Infarction: Preliminary Results Of A Randomized Study]] | ||
|- | |- | ||
| ER-TIMI | | [[ER-TIMI]] | ||
| [[Early Retavase - Thrombolysis In Myocardial Infarction]] | | [[Early Retavase - Thrombolysis In Myocardial Infarction]] | ||
|- | |- | ||
| ESCAMI | | [[ESCAMI]] | ||
| [[Evaluation Of The Safety And Cardioprotective Effects Of Eniporide In Acute Myocardial Infarction]] | | [[Evaluation Of The Safety And Cardioprotective Effects Of Eniporide In Acute Myocardial Infarction]] | ||
|- | |- | ||
| ESCAPE | | [[ESCAPE]] | ||
| [[Evaluation Study Of Congestive Heart Failure And Pulmonary Artery Catheterization Effectiveness]] | | [[Evaluation Study Of Congestive Heart Failure And Pulmonary Artery Catheterization Effectiveness]] | ||
|- | |- | ||
| ESCAPE | | [[ESCAPE]] | ||
| [[Evaluation Study Of Congestive Heart Failure And Pulmonary Artery Catheterization Effectiveness]] | | [[Evaluation Study Of Congestive Heart Failure And Pulmonary Artery Catheterization Effectiveness]] | ||
|- | |- | ||
| E-SIRIUS | | [[E-SIRIUS]] | ||
| [[European Sirolimus-Eluting Stent In Coronary Lesions]] | | [[European Sirolimus-Eluting Stent In Coronary Lesions]] | ||
|- | |- | ||
| ESPRIT | | [[ESPRIT]] | ||
| [[Enhanced Suppression Of The Platelet IIb/IIia Receptor With Integrilin TherapyEuropean Study Of The Prevention Of Reocclusion After Initial ThrombolysisEvaluation Of Subcutaneous Proleukin In A Randomized International Trial]] | | [[Enhanced Suppression Of The Platelet IIb/IIia Receptor With Integrilin TherapyEuropean Study Of The Prevention Of Reocclusion After Initial ThrombolysisEvaluation Of Subcutaneous Proleukin In A Randomized International Trial]] | ||
|- | |- | ||
| ESPRIT HRT | | [[ESPRIT HRT]] | ||
| [[Oestrogen In The Prevention Of Reinfarction Trial]] | | [[Oestrogen In The Prevention Of Reinfarction Trial]] | ||
|- | |- | ||
| ESPS2 | | [[ESPS2]] | ||
| [[European Stroke Prevention Study 2]] | | [[European Stroke Prevention Study 2]] | ||
|- | |- | ||
| ESPS-2 | | [[ESPS-2]] | ||
| [[European Stroke Prevention Study 2]] | | [[European Stroke Prevention Study 2]] | ||
|- | |- | ||
| ESSENCE | | [[ESSENCE]] | ||
| [[Efficacy And Safety Of Subcutaneous Enoxaparin In Unstable Angina And Non-Q-Wave Mi]] | | [[Efficacy And Safety Of Subcutaneous Enoxaparin In Unstable Angina And Non-Q-Wave Mi]] | ||
|- | |- | ||
| ESSENCE | | [[ESSENCE]] | ||
| [[Efficacy And Safety Of Subcutaneous Enoxaparin In Non–Q-Wave Coronary Events ]] | | [[Efficacy And Safety Of Subcutaneous Enoxaparin In Non–Q-Wave Coronary Events ]] | ||
|- | |- | ||
| ESSENTIAL | | [[ESSENTIAL]] | ||
| [[The Studies Of Oral Enoximone Therapy In Advanced Heart Failure]] | | [[The Studies Of Oral Enoximone Therapy In Advanced Heart Failure]] | ||
|- | |- | ||
| ESSENTIAL | | [[ESSENTIAL]] | ||
| [[The Studies Of Oral Enoximone Therapy In Advanced Heart Failure]] | | [[The Studies Of Oral Enoximone Therapy In Advanced Heart Failure]] | ||
|- | |- | ||
| ESTAT | | [[ESTAT]] | ||
| [[European Stroke Treatment With Ancrod Trial]] | | [[European Stroke Treatment With Ancrod Trial]] | ||
|- | |- | ||
| ESTEEM | | [[ESTEEM]] | ||
| [[Efficacy And Safety Of The Oral Direct Thrombin Inhibitor Ximelagatran In Patients After Acute Myocardial Infarction]] | | [[Efficacy And Safety Of The Oral Direct Thrombin Inhibitor Ximelagatran In Patients After Acute Myocardial Infarction]] | ||
|- | |- | ||
| ESVEM | | [[ESVEM]] | ||
| [[Electrophysiologic Study Versus Electrocardiographic Monitoring Trial]] | | [[Electrophysiologic Study Versus Electrocardiographic Monitoring Trial]] | ||
|- | |- | ||
| ETHECC | | [[ETHECC]] | ||
| [[Evaluation Of Thymitaq In Hepatocellular Carcinoma]] | | [[Evaluation Of Thymitaq In Hepatocellular Carcinoma]] | ||
|- | |- | ||
| ETICA | | [[ETICA]] | ||
| [[Exercise Training Intervention After Coronary Angioplasty: The Etica Trial]] | | [[Exercise Training Intervention After Coronary Angioplasty: The Etica Trial]] | ||
|- | |- | ||
| ETROP | | [[ETROP]] | ||
| [[Early Treatment Of Retinopathy Of Prematurity]] | | [[Early Treatment Of Retinopathy Of Prematurity]] | ||
|- | |- | ||
| EURIDIS and ADONIS | | [[EURIDIS and ADONIS]] | ||
| [[Maintenance Of Sinus Rhythm With Dronedarone In Patients With Atrial Fibrillation Or Flutter]] | | [[Maintenance Of Sinus Rhythm With Dronedarone In Patients With Atrial Fibrillation Or Flutter]] | ||
|- | |- | ||
| EUROACTION | | [[EUROACTION]] | ||
| [[Nurse-Coordinated Multidisciplinary, Family-Based Cardiovascular Disease Prevention Programme]] | | [[Nurse-Coordinated Multidisciplinary, Family-Based Cardiovascular Disease Prevention Programme]] | ||
|- | |- | ||
| EUROCARE | | [[EUROCARE]] | ||
| [[Carvedilol For Prevention Of Restenosis After Directional Coronary Atherectomy]] | | [[Carvedilol For Prevention Of Restenosis After Directional Coronary Atherectomy]] | ||
|- | |- | ||
| EUROPA | | [[EUROPA]] | ||
| [[European Trial On Reduction Of Cardiac Events With Perindopril In Stable Coronary Artery Disease]] | | [[European Trial On Reduction Of Cardiac Events With Perindopril In Stable Coronary Artery Disease]] | ||
|- | |- | ||
| EURO-SPAH | | [[EURO-SPAH]] | ||
| [[European Sonotherapy Trial To Prevent Arterial Hyperplasia]] | | [[European Sonotherapy Trial To Prevent Arterial Hyperplasia]] | ||
|- | |- | ||
| Euro-SPAH | | [[Euro-SPAH]] | ||
| [[European-Sonotherapy Prevention Of Arterial Hyperplasia]] | | [[European-Sonotherapy Prevention Of Arterial Hyperplasia]] | ||
|- | |- | ||
| EUROSTAR | | [[EUROSTAR]] | ||
| [[European Cobalt Stent With Antiproliferative For Restenosis Trial]] | | [[European Cobalt Stent With Antiproliferative For Restenosis Trial]] | ||
|- | |- | ||
| EUTOPIA | | [[EUTOPIA]] | ||
| [[European Trial On Olmesartan And Pravastatin In Inflammation And Atherosclerosis]] | | [[European Trial On Olmesartan And Pravastatin In Inflammation And Atherosclerosis]] | ||
|- | |- | ||
| EVA | | [[EVA]] | ||
| [[Common Carotid Intima-Media Thickness Predicts Occurrence Of Carotid Atherosclerotic Plaques: Longitudinal Results From The Aging Vascular Study]] | | [[Common Carotid Intima-Media Thickness Predicts Occurrence Of Carotid Atherosclerotic Plaques: Longitudinal Results From The Aging Vascular Study]] | ||
|- | |- | ||
| EVA-AMI | | [[EVA-AMI]] | ||
| [[Eptifibatide Versus Abciximab In Primary Pci For Acute St Elevation Myocardial Infarction]] | | [[Eptifibatide Versus Abciximab In Primary Pci For Acute St Elevation Myocardial Infarction]] | ||
|- | |- | ||
| EVEREST | | [[EVEREST]] | ||
| [[Efficacy Of Vasopressin Antagonism In Heart Failure: Outcome Study With Tolvaptan]] | | [[Efficacy Of Vasopressin Antagonism In Heart Failure: Outcome Study With Tolvaptan]] | ||
|- | |- | ||
| EVEREST I | | [[EVEREST I]] | ||
| [[Endovascular Valve Edge-To-Edge Repair Study]] | | [[Endovascular Valve Edge-To-Edge Repair Study]] | ||
|- | |- | ||
| EVET | | [[EVET]] | ||
| [[Enoxaparin Versus Tinzaparin In Non-St-Segment Elevation Acute Coronary Syndromes]] | | [[Enoxaparin Versus Tinzaparin In Non-St-Segment Elevation Acute Coronary Syndromes]] | ||
|- | |- | ||
| EVIDENCE | | [[EVIDENCE]] | ||
| [[Evidence For Interferon Dose-Effect: European-North American Comparative Efficacy Study (Rebif V. Avonex In Relapsing-Remitting Multiple Sclerosis (Rrms))]] | | [[Evidence For Interferon Dose-Effect: European-North American Comparative Efficacy Study (Rebif V. Avonex In Relapsing-Remitting Multiple Sclerosis (Rrms))]] | ||
|- | |- | ||
| EVIDENT | | [[EVIDENT]] | ||
| [[Endo-Vascular Investigation Determining The Safety Of A New Tacrolimus Eluting Stent Graft]] | | [[Endo-Vascular Investigation Determining The Safety Of A New Tacrolimus Eluting Stent Graft]] | ||
|- | |- | ||
| EVIDENT | | [[EVIDENT]] | ||
| [[Endovascular Investigation Determining The Safety Of A New Tacrolimus-Eluting Stent Graft]] | | [[Endovascular Investigation Determining The Safety Of A New Tacrolimus-Eluting Stent Graft]] | ||
|- | |- | ||
| EXCITE | | [[EXCITE]] | ||
| [[Evaluation Of Oral Xemilofiban In Controlling Thrombotic Events]] | | [[Evaluation Of Oral Xemilofiban In Controlling Thrombotic Events]] | ||
|- | |- | ||
| EXCITE | | [[EXCITE]] | ||
| [[Evaluation Of Oral Xemilofiban In Controlling Thrombotic Events ]] | | [[Evaluation Of Oral Xemilofiban In Controlling Thrombotic Events ]] | ||
|- | |- | ||
| EXCITe | | [[EXCITe]] | ||
| [[Extremity Constraint-Induced Therapy]] | | [[Extremity Constraint-Induced Therapy]] | ||
|- | |- | ||
| EXCLAIM | | [[EXCLAIM]] | ||
| [[Extended Clinical Prophylaxis In Acutely Ill Medical Patients (Lovenox (Enoxaparin) Postmarketing (Phase Iv) Trial) ]] | | [[Extended Clinical Prophylaxis In Acutely Ill Medical Patients (Lovenox (Enoxaparin) Postmarketing (Phase Iv) Trial) ]] | ||
|- | |- | ||
| EXPEDITION | | [[EXPEDITION]] | ||
| [[Na+/H+ Exchange Inhibition To Prevent Coronary Events In Acute Cardiac Conditions]] | | [[Na+/H+ Exchange Inhibition To Prevent Coronary Events In Acute Cardiac Conditions]] | ||
|- | |- | ||
| EXPIRA | | [[EXPIRA]] | ||
| [[ Thrombectomy With Export Catheter In Infarct-Related Artery During Primary Percutaneous Coronary Intervention]] | | [[ Thrombectomy With Export Catheter In Infarct-Related Artery During Primary Percutaneous Coronary Intervention]] | ||
|- | |- | ||
| ExTRACT | | [[ExTRACT]] | ||
| [[Enoxaparin And Thrombolysis Reperfusion For Acute Myocardial Infarction Treatment]] | | [[Enoxaparin And Thrombolysis Reperfusion For Acute Myocardial Infarction Treatment]] | ||
|- | |- | ||
| F.I.R.E. | | [[F.I.R.E.]] | ||
| [[Efficacy Of Fx06 In The Prevention Of Myocardial Reperfusion Injury Trial]] | | [[Efficacy Of Fx06 In The Prevention Of Myocardial Reperfusion Injury Trial]] | ||
|- | |- | ||
| FAAT | | [[FAAT]] | ||
| [[Fatty Acid Antiarrhythmia Trial]] | | [[Fatty Acid Antiarrhythmia Trial]] | ||
|- | |- | ||
| FACET | | [[FACET]] | ||
| [[Flosequinan - Ace Inhibition Trial]] | | [[Flosequinan - Ace Inhibition Trial]] | ||
|- | |- | ||
| FACET | | [[FACET]] | ||
| [[Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial]] | | [[Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial]] | ||
|- | |- | ||
| FACIT | | [[FACIT]] | ||
| [[Folate After Coronary Intervention Trial]] | | [[Folate After Coronary Intervention Trial]] | ||
|- | |- | ||
| FACT | | [[FACT]] | ||
| [[Effect Of Nadroparin, A Low-Molecular-Weight Heparin, On Clinical And Angiographic Restenosis After Coronary Balloon Angioplasty]] | | [[Effect Of Nadroparin, A Low-Molecular-Weight Heparin, On Clinical And Angiographic Restenosis After Coronary Balloon Angioplasty]] | ||
|- | |- | ||
| FAME | | [[FAME]] | ||
| [[Fractional Flow Reserve Versus Angiography For Multivessel Evaluation]] | | [[Fractional Flow Reserve Versus Angiography For Multivessel Evaluation]] | ||
|- | |- | ||
| FAME | | [[FAME]] | ||
| [[Fluvastatin (Lescol) Assessment Of Morbi-Mortality In The Elderly]] | | [[Fluvastatin (Lescol) Assessment Of Morbi-Mortality In The Elderly]] | ||
|- | |- | ||
| FAMIS | | [[FAMIS]] | ||
| [[Fosinopril In Acute Myocardial Infarction Study]] | | [[Fosinopril In Acute Myocardial Infarction Study]] | ||
|- | |- | ||
| FANTASTIC | | [[FANTASTIC]] | ||
| [[Randomized Multicenter Comparison Of Conventional Anticoagulation Versus Antiplatelet Therapy In Unplanned And Elective Coronary Stenting]] | | [[Randomized Multicenter Comparison Of Conventional Anticoagulation Versus Antiplatelet Therapy In Unplanned And Elective Coronary Stenting]] | ||
|- | |- | ||
| FAST | | [[FAST]] | ||
| [[Femoral Artery Stenting Trial]] | | [[Femoral Artery Stenting Trial]] | ||
|- | |- | ||
| FASTER | | [[FASTER]] | ||
| [[Fibrinolytic And Aggrastat St Elevation Resolution First Abarelix Depot Study For Treating Endometriosis RapidlyFirst And Second Trimester Evaluation Of Risk]] | | [[Fibrinolytic And Aggrastat St Elevation Resolution First Abarelix Depot Study For Treating Endometriosis RapidlyFirst And Second Trimester Evaluation Of Risk]] | ||
|- | |- | ||
| FAST-MAG | | [[FAST-MAG]] | ||
| [[Field Administration Of Stroke Therapy - Magnesium]] | | [[Field Administration Of Stroke Therapy - Magnesium]] | ||
|- | |- | ||
| FATS | | [[FATS]] | ||
| [[Familial Atherosclerosis Treatment Study]] | | [[Familial Atherosclerosis Treatment Study]] | ||
|- | |- | ||
| FEMINA | | [[FEMINA]] | ||
| [[Addition Of Felodipine To Metoprolol Vs. Replacement Of Metoprolol By Felodipine In Patients With Angina Pectoris Despite Adequate Beta-Blockade]] | | [[Addition Of Felodipine To Metoprolol Vs. Replacement Of Metoprolol By Felodipine In Patients With Angina Pectoris Despite Adequate Beta-Blockade]] | ||
|- | |- | ||
| FERRIC-HF | | [[FERRIC-HF]] | ||
| [[Effect Of Intravenous Ferrous Sucrose On Exercise Capacity In Chronic Heart Failure]] | | [[Effect Of Intravenous Ferrous Sucrose On Exercise Capacity In Chronic Heart Failure]] | ||
|- | |- | ||
| FEST | | [[FEST]] | ||
| [[Fosinopril Efficacy/Safety Trial]] | | [[Fosinopril Efficacy/Safety Trial]] | ||
|- | |- | ||
| FIELD | | [[FIELD]] | ||
| [[Fenofibrate Intervention And Event Lowering In Diabetes]] | | [[Fenofibrate Intervention And Event Lowering In Diabetes]] | ||
|- | |- | ||
| FIELD | | [[FIELD]] | ||
| [[Fenofibrate (Tricor) Intervention And Event Lowering In Diabetes]] | | [[Fenofibrate (Tricor) Intervention And Event Lowering In Diabetes]] | ||
|- | |- | ||
| FINESSE | | [[FINESSE]] | ||
| [[Facilitated Intervention With Enhanced Reperfusion Speed To Stop Events]] | | [[Facilitated Intervention With Enhanced Reperfusion Speed To Stop Events]] | ||
|- | |- | ||
| FIRE | | [[FIRE]] | ||
| [[Filterwire Ex Randomized Evaluation]] | | [[Filterwire Ex Randomized Evaluation]] | ||
|- | |- | ||
| FIRST | | [[FIRST]] | ||
| [[Flolan International Randomized Survival Trial (Phase IIi (Develop Economic Data))]] | | [[Flolan International Randomized Survival Trial (Phase IIi (Develop Economic Data))]] | ||
|- | |- | ||
| FIRST | | [[FIRST]] | ||
| [[Flolan (Dobutamine) International Randomized Survival Trial First Trimester Integrated Risk Screening For Trisomy]] | | [[Flolan (Dobutamine) International Randomized Survival Trial First Trimester Integrated Risk Screening For Trisomy]] | ||
|- | |- | ||
| FLARE | | [[FLARE]] | ||
| [[Fluvastatin Angioplasty Restenosis]] | | [[Fluvastatin Angioplasty Restenosis]] | ||
|- | |- | ||
| FLARE | | [[FLARE]] | ||
| [[Fluvastatin (Lescol) Angiographic Restenosis]] | | [[Fluvastatin (Lescol) Angiographic Restenosis]] | ||
|- | |- | ||
| FLORIDA | | [[FLORIDA]] | ||
| [[Fluvastatin On Risk Diminishing After Acute Myocardial Infarction]] | | [[Fluvastatin On Risk Diminishing After Acute Myocardial Infarction]] | ||
|- | |- | ||
| FLUCAD | | [[FLUCAD]] | ||
| [[Influenza Vaccination In Secondary Prevention From Coronary Ischemic Events In Coronary Artery Disease]] | | [[Influenza Vaccination In Secondary Prevention From Coronary Ischemic Events In Coronary Artery Disease]] | ||
|- | |- | ||
| FOOD | | [[FOOD]] | ||
| [[Feed Or Ordinary Diet]] | | [[Feed Or Ordinary Diet]] | ||
|- | |- | ||
| FOSIT | | [[FOSIT]] | ||
| [[Fosamax International Trial]] | | [[Fosamax International Trial]] | ||
|- | |- | ||
| FRAXIS | | [[FRAXIS]] | ||
| [[Fraxiparin Versus Unfractionated Heparin In The Treatment Of Unstable Angina]] | | [[Fraxiparin Versus Unfractionated Heparin In The Treatment Of Unstable Angina]] | ||
|- | |- | ||
| FRAXIS / FRAX.I.S. | | [[FRAXIS / FRAX.I.S.]] | ||
| [[Fraxiparine In Ischemic Syndromes]] | | [[Fraxiparine In Ischemic Syndromes]] | ||
|- | |- | ||
| FRESCO | | [[FRESCO]] | ||
| [[Investigators In The Florence Randomized Elective Stenting In Acute Coronary Occlusions]] | | [[Investigators In The Florence Randomized Elective Stenting In Acute Coronary Occlusions]] | ||
|- | |- | ||
| FRIC | | [[FRIC]] | ||
| [[Fragmin In Unstable Coronary Artery Disease]] | | [[Fragmin In Unstable Coronary Artery Disease]] | ||
|- | |- | ||
| FRIC | | [[FRIC]] | ||
| [[Fragmin In Unstable Coronary Artery Disease]] | | [[Fragmin In Unstable Coronary Artery Disease]] | ||
|- | |- | ||
| FRISC | | [[FRISC]] | ||
| [[Fast Revascularization During Instability In Coronary Artery Disease]] | | [[Fast Revascularization During Instability In Coronary Artery Disease]] | ||
|- | |- | ||
| FRISC II | | [[FRISC II]] | ||
| [[Fragmin And Fast Revascularization During Instability In Coronary Artery Disease]] | | [[Fragmin And Fast Revascularization During Instability In Coronary Artery Disease]] | ||
|- | |- | ||
| FROST | | [[FROST]] | ||
| [[French Optimal Stenting Trial]] | | [[French Optimal Stenting Trial]] | ||
|- | |- | ||
| FROSTY | | [[FROSTY]] | ||
| [[Freezor Trial Of Supraventricular Tachycardia]] | | [[Freezor Trial Of Supraventricular Tachycardia]] | ||
|- | |- | ||
| FTT | | [[FTT]] | ||
| [[Fibrinolytic Therapy Trialists' Collaborative Group]] | | [[Fibrinolytic Therapy Trialists' Collaborative Group]] | ||
|- | |- | ||
| FUSION | | [[FUSION]] | ||
| [[Fractional Flow Reserve And Ultrasound Indices For Objective Narrowing Assessment]] | | [[Fractional Flow Reserve And Ultrasound Indices For Objective Narrowing Assessment]] | ||
|- | |- | ||
| FUSION I | | [[FUSION I]] | ||
| [[Follow-Up Serial Infusions Of Nesiritide Trial]] | | [[Follow-Up Serial Infusions Of Nesiritide Trial]] | ||
|- | |- | ||
| FUTURE I | | [[FUTURE I]] | ||
| [[First Use To Underscore Restenosis Reduction With Everolimus]] | | [[First Use To Underscore Restenosis Reduction With Everolimus]] | ||
|- | |- | ||
| FUTURE II | | [[FUTURE II]] | ||
| [[Multicenter Evaluation Of The Biosbsorbable Polymer-Based Everolimus-Eluting Stent]] | | [[Multicenter Evaluation Of The Biosbsorbable Polymer-Based Everolimus-Eluting Stent]] | ||
|- | |- | ||
| GABI | | [[GABI]] | ||
| [[German Angioplasty Vs. Bypass Surgery Investigation]] | | [[German Angioplasty Vs. Bypass Surgery Investigation]] | ||
|- | |- | ||
| GABI-2 | | [[GABI-2]] | ||
| [[German Angioplasty Bypass Investigation - 2]] | | [[German Angioplasty Bypass Investigation - 2]] | ||
|- | |- | ||
| GAMI | | [[GAMI]] | ||
| [[ Glucose Abnormalities In Patients With Myocardial Infarction: Prevalence, Diagnosis, And Prognostic Implications]] | | [[ Glucose Abnormalities In Patients With Myocardial Infarction: Prevalence, Diagnosis, And Prognostic Implications]] | ||
|- | |- | ||
| GAMMA II | | [[GAMMA II]] | ||
| [[Gamma II Localized Radiation Therapy To Inhibit Restenosis]] | | [[Gamma II Localized Radiation Therapy To Inhibit Restenosis]] | ||
|- | |- | ||
| GAMMA V | | [[GAMMA V]] | ||
| [[Gamma V Localized Radiation Therapy To Inhibit Restenosis]] | | [[Gamma V Localized Radiation Therapy To Inhibit Restenosis]] | ||
|- | |- | ||
| Gamma-One | | [[Gamma-One]] | ||
| [[Localized Intracoronary Gamma-Radiation Therapy To Inhibit The Recurrence Of Restenosis After Stenting]] | | [[Localized Intracoronary Gamma-Radiation Therapy To Inhibit The Recurrence Of Restenosis After Stenting]] | ||
|- | |- | ||
| GART study | | [[GART study]] | ||
| [[Genotypic Antiretroviral Resistance Testing]] | | [[Genotypic Antiretroviral Resistance Testing]] | ||
|- | |- | ||
| GEMICA | | [[GEMICA]] | ||
| [[Morbidity And Mortality Following Early Administration Of Amiodarone In Myocardial Infarction]] | | [[Morbidity And Mortality Following Early Administration Of Amiodarone In Myocardial Infarction]] | ||
|- | |- | ||
| GEMINI | | [[GEMINI]] | ||
| [[Glycemic Effects In Diabetes Mellitus: Carvedilol - Metoprolol Comparison In Hypertensives Trial]] | | [[Glycemic Effects In Diabetes Mellitus: Carvedilol - Metoprolol Comparison In Hypertensives Trial]] | ||
|- | |- | ||
| GEMS | | [[GEMS]] | ||
| [['Ginkgo Biloba 'Evaluation Memory Study]] | | [['Ginkgo Biloba 'Evaluation Memory Study]] | ||
|- | |- | ||
| GENESIS | | [[GENESIS]] | ||
| [[A Randomized, Multicenter Study Of The Pimecrolimus-Eluting And Pimecrolimus/Paclitaxel-Eluting Coronary Stent System In Patients With De Novo Lesions Of The Native Coronary Arteries]] | | [[A Randomized, Multicenter Study Of The Pimecrolimus-Eluting And Pimecrolimus/Paclitaxel-Eluting Coronary Stent System In Patients With De Novo Lesions Of The Native Coronary Arteries]] | ||
|- | |- |
Latest revision as of 20:38, 8 August 2012
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
For other acronyms involved in clinical trials, click here
For detailed instructions on how to contribute to WikiDoc's Clinical Trials Wiki, click here